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Abstract
The American College of Cardiology Foundation (ACCF), in
partnership with the American Society of Echocardiography
(ASE) and along with key specialty and subspecialty societies,
conducted a review of common clinical scenarios where echo-
cardiography is frequently considered. This document com-
bines and updates the original transthoracic and transesopha-
geal echocardiography appropriateness criteria published in
2007 (1) and the original stress echocardiography appropriate-
ness criteria published in 2008 (2). This revision reflects new
clinical data, reflects changes in test utilization patterns, and
clarifies echocardiography use where omissions or lack of
clarity existed in the original criteria.
The indications (clinical scenarios) were derived from com-
mon applications or anticipated uses, as well as from current
clinical practice guidelines and results of studies examining the
implementation of the original appropriate use criteria (AUC).
The 202 indications in this document were developed by a
diverse writing group and scored by a separate independent
technical panel on a scale of 1 to 9, to designate appropriate use
(median 7 to 9), uncertain use (median 4 to 6), and inappro-
priate use (median 1 to 3).
Ninety-seven indications were rated as appropriate, 34 were
rated as uncertain, and 71 were rated as inappropriate. In
general, the use of echocardiography for initial diagnosis when
there is a change in clinical status or when the results of the
echocardiogram are anticipated to change patient management
were rated appropriate. Routine testing when there was no
change in clinical status or when results of testing were unlikely
to modify management were more likely to be inappropriate
than appropriate/uncertain.
The AUC for echocardiography have the potential to
impact physician decision making, healthcare delivery, and
reimbursement policy. Furthermore, recognition of uncer-
tain clinical scenarios facilitates identification of areas that
would benefit from future research.
Preface
In an effort to respond to the need for the rational use of
imaging services in the delivery of high-quality care, the
ACCF has undertaken a process to determine the appropriate
use of cardiovascular imaging for selected patient indications.
AUC publications reflect an ongoing effort by the ACCF to
critically and systematically create, review, and categorize clin-ical situations where diagnostic tests and procedures are uti-
lized by physicians caring for patients with cardiovascular
diseases. The process is based on current understanding of the
technical capabilities of the imaging modalities examined.
Although impossible to be entirely comprehensive given the
wide diversity of clinical disease, the indications are meant to
identify common scenarios encompassing the majority of
situations encountered in contemporary practice. Given the
breadth of information they convey, the indications do not
directly correspond to the Ninth Revision of the International
Classification of Diseases system as these codes do not include
clinical information, such as symptom status.
The ACCF believes that careful blending of a broad range
of clinical experiences and available evidence-based informa-
tion will help guide a more efficient and equitable allocation of
healthcare resources in cardiovascular imaging. The ultimate
objective of AUC is to improve patient care and health
outcomes in a cost-effective manner, but it is not intended to
ignore ambiguity and nuance intrinsic to clinical decision
making. AUC thus should not be considered substitutes for
sound clinical judgment and practice experience.
The ACCF AUC process itself is also evolving. In the
current iteration, technical panel members were asked to rate
indications for echocardiography in a manner independent and
irrespective of the prior published ACCF ratings for transtho-
racic echocardiography (TTE) and transesophageal echocardi-
ography (TEE) (1) and stress echocardiography (2) as well as
the prior ACCF ratings for diagnostic imaging modalities such
as cardiac radionuclide imaging (RNI) (3) and cardiac com-
puted tomography (CT) (4). Given the iterative and evolving
nature of the process, readers are counseled that comparison of
individual appropriate use ratings among modalities rated at
different times over the past several years may not reflect the
comparative utility of the different modalities for an indication,
as the ratings may vary over time. A comparative evaluation of
the appropriate use of multiple imaging techniques is currently
being undertaken to assess the relative strengths of each
modality for various clinical scenarios.
We are grateful to the technical panel and its chair, Steven
Bailey, MD, FACC, FSCAI, FAHA, a professional group
with a wide range of skills and insights, for their thoughtful
and thorough deliberation of the merits of echocardiography
for various indications. We would also like to thank the 27
individuals who provided a careful review of the draft of
indications, the parent AUC Task Force ably led by Michael
Wolk, MD, MACC, Rory Weiner, MD, and the ACC staff,
John C. Lewin, MD, Joseph Allen, Starr Webb, Jenissa
Haidari, and Lea Binder for their exceptionally skilled support
in the generation of this document.
Pamela S. Douglas, MD, MACC, FAHA, FASE
Chair, Echocardiography Writing Group
Michael J. Wolk, MD, MACC
Chair, Appropriate Use Criteria Task Force
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This report addresses the appropriate use of TTE, TEE, and
stress echocardiography. Improvements in cardiovascular im-
aging technology and an expanding armamentarium of non-
invasive diagnostic tools and therapeutic options for cardiovas-
cular disease have led to an increase in cardiovascular imaging.
As the field of echocardiography continues to advance along
with other imaging modalities and treatment options, the
healthcare community needs to understand how to best incor-
porate this technology into daily clinical care.
All prior AUC publications from the ACCF and collab-
orating organizations reflect an ongoing effort to critically
and systematically create, review, and categorize the appro-
priate use of cardiovascular procedures and diagnostic tests.
The ACCF recognizes the importance of revising these
criteria in a timely manner in order to provide the cardio-
vascular community with the most accurate indications.
Understanding the background and scope of this document
are important before interpreting the rating tables.
This document presents a combination and revision of
the 2007 ACCF AUC for Transthoracic and Transesoph-
ageal Echocardiography (1) and the 2008 ACCF AUC for
Stress Echocardiography (2). Appropriate echocardiograms
are those that are likely to contribute to improving patients’
clinical outcomes, and importantly, inappropriate use of
echocardiography may be potentially harmful to patients
and generate unwarranted costs to the healthcare system.
2. Methods
The indications included in this publication cover a wide
array of cardiovascular signs and symptoms as well as clinical
judgments as to the likelihood of cardiovascular findings.
Within each main disease category, a standardized approach
was used to capture the majority of clinical scenarios
without making the list of indications excessive. The ap-
proach was to create 5 broad clinical scenarios regarding the
possible use of echocardiography: 1) for initial diagnosis; 2)
to guide therapy or management, regardless of symptom
status; 3) to evaluate a change in clinical status or cardiac
exam; 4) for early follow-up without change in clinical
status; and 5) for late follow-up without change in clinical
status. Certain specific clinical scenarios were addressed
with additional focused indications.
The indications were constructed by experts in echocar-
diography and in other fields and were modified on the basis
of discussions among the task force and feedback from
independent reviewers and the technical panel. Wherever
possible, indications were mapped to relevant clinical guide-
lines and key publications/references (Online Appendix).
An important focus during the indication revision process
was to harmonize the indications across noninvasive modal-
ities, such that the wording of the indications are similar
with other AUC (3) whenever it was feasible to do so. Newindications as well as indication tables were created, al-
though it remains likely that several clinical scenarios are not
covered by these revised AUC for echocardiography. Once
the revised indications were written, they were reviewed and
critiqued by the parent AUC Task Force and by 27 external
reviewers representing all cardiovascular specialties and
primary care before being finalized.
A detailed description of the methods used for ranking
the selected clinical indications is found in a previous
publication, “ACCF Proposed Method for Evaluating the
Appropriateness of Cardiovascular Imaging” (5). Briefly,
this process combines evidence-based medicine and practice
experience by engaging a technical panel in a modified
Delphi exercise. Since the original TTE/TEE (1) and stress
echocardiography (2) documents and methods paper (5)
were published, several important processes have been put in
place to further enhance the rigor of this process. They
include convening a formal writing group with diverse
expertise in imaging and clinical care, circulating the indi-
cations for external review prior to rating by the technical
panel, ensuring appropriate balance of expertise and practice
area of the technical panel, development of a standardized
rating package, and establishment of formal roles for facil-
itating panel interaction at the face-to-face meeting.
The technical panel first rated indications independently.
Then, the panel was convened for a face-to-face meeting for
discussion of each indication. At this meeting, panel mem-
bers were provided with their scores and a blinded summary
of their peers’ scores. After the meeting, panel members
were then asked to independently provide their final scores
for each indication.
Although panel members were not provided explicit cost
information to help determine their appropriate use ratings,
they were asked to implicitly consider cost as an additional
factor in their evaluation of appropriate use. In rating these
criteria, the technical panel was asked to assess whether the
use of the test for each indication is appropriate, uncertain,
or inappropriate, and was provided the following definition
of appropriate use:
An appropriate imaging study is one in which the expected
incremental information, combined with clinical judgment,
exceeds the expected negative consequences* by a sufficiently
wide margin for a specific indication that the procedure is
generally considered acceptable care and a reasonable ap-
proach for the indication.
The technical panel scored each indication as follows:
Median Score 7 to 9
Appropriate test for specific indication (test is generally
acceptable and is a reasonable approach for the
indication).
*Negative consequences include the risks of the procedure (i.e., radiation or contrast
exposure) and the downstream impact of poor test performance such as delay in
diagnosis (false-negatives) or inappropriate diagnosis (false-positives).
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Uncertain for specific indication (test may be generally
acceptable and may be a reasonable approach for the
indication). Uncertainty also implies that more re-
search and/or patient information is needed to classify
the indication definitively.
Median Score 1 to 3
Inappropriate test for that indication (test is not gener-
ally acceptable and is not a reasonable approach for
the indication).
The division of these scores into 3 levels of appropriate-
ess is somewhat arbitrary, and the numeric designations
hould be viewed as a continuum. Further, there is diversity
n clinical opinion for particular clinical scenarios, such that
cores in the intermediate level of appropriate use should be
abeled “uncertain,” as critical patient or research data may
e lacking or discordant. This designation should be a
rompt to the field to carry out definitive research investi-
ations whenever possible. It is anticipated that the AUC
eports will continue to be revised as further data are
enerated and information from the implementation of the
riteria is accumulated.
To prevent bias in the scoring process, the technical panel
as deliberately comprised of a minority of specialists in
chocardiography. Specialists, although offering important
linical and technical insights, might have a natural ten-
ency to rate the indications within their specialty as more
ppropriate than nonspecialists. In addition, care was taken
n providing objective, nonbiased information, including
uidelines and key references, to the technical panel.
The level of agreement among panelists as defined by
AND (6) was analyzed based on the BIOMED rule for a
anel of 14 to 16 members. As such, agreement was defined
s an indication where 4 or fewer panelists’ ratings fell
utside the 3-point region containing the median score.
Disagreement was defined as where at least 5 panelists’
atings fell in both the appropriate and the inappropriate
ategories. Any indication having disagreement was catego-
ized as uncertain regardless of the final median score.
ndications that met neither definition for agreement or
isagreement are in a third, unlabeled category.
3. General Assumptions
To prevent any inconsistencies in interpretation, specific as-
sumptions were considered by the writing group in developing
the indications and by the technical panel when rating the
clinical indications for the appropriate use of inpatient and
outpatient adult TTE/TEE and stress echocardiography.
1. A TTE and a TEE examination and report will include
the use and interpretation of 2-dimensional/M-mode
imaging, color flow Doppler, and spectral Doppler as
important elements of a comprehensive TTE/TEE(7–9) evaluating relevant cardiac structures and hemo-
dynamics. Stress echocardiography will include rest and
stress 2-dimensional imaging at a minimum unless
performed for hemodynamics, when Doppler must be
included (10).
2. All standard echocardiographic techniques for image
acquisition, including standard rest imaging and stress
protocols (10), are available for each indication and
have a sensitivity and specificity similar to those found
in the published literature. Selection for and monitoring
of contrast use is assumed to be in accord with practice
guidelines (11).
3. The test is performed and interpreted by qualified
individual(s) in a facility that is proficient in the
echocardiographic technique (12,13).
4. The range of potential indications for echocardiography
is quite large, particularly in comparison with other
cardiovascular imaging tests. Thus, the indications are,
at times, purposefully broad to cover an array of
cardiovascular signs and symptoms as well as the
ordering physician’s best judgment as to the presence of
cardiovascular abnormalities. Additionally, there are
likely clinical scenarios that are not covered in this
document.
5. A complete clinical history and physical exam has been
completed by a qualified clinician such that the clinical
status of the patient can be assumed to be valid as stated
in the indication (e.g., an asymptomatic patient is truly
asymptomatic for the condition in question and that
sufficient questioning of the patient has been under-
taken).
6. If the reason for a test can be assigned to more than 1
indication, it should be classified under the most
appropriate indication.
7. Cost should be considered implicitly in the appropriate
use determination.
8. For each indication, the rating should reflect whether
the echocardiogram is reasonable for the patient ac-
cording to the appropriate use definition, not whether
the test is preferred over another modality. It should not
be assumed that for each indication the decision to
perform a diagnostic test has already been made. It also
should not consider issues of local availability or skill for
any modality or attempt in any way to compare 2 tests
with each other.
9. The category of “uncertain” should be used when
insufficient clinical data are available for a definitive
categorization or there is substantial disagreement re-
garding the appropriateness of that indication. The
designation of “uncertain” should not be used as
grounds for denial of reimbursement.
10. Indications that describe routine or surveillance echo-
cardiograms imply that the test is being considered for
a “periodic” evaluation since a certain period of time has
elapsed. The test is not being ordered due to the
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guiding therapy.
1. Prosthetic valves and native valves are to be considered
together, except where specifically mentioned otherwise
in this document. The severity of valve stenosis or
regurgitation is defined in clinical guidelines (14,15).
2. In general, it is assumed that TEE is most appropriately
used as an adjunct or subsequent test to TTE when
indicated, such as when suboptimal TTE images pre-
clude obtaining a diagnostic study. The indications for
which TEE may reasonably be the test of first choice
include, but are not limited to, the indications pre-
sented in Table 8 of this document.
3. Intraoperative TEE is an important use of cardiovas-
cular ultrasound. However, this application is outside
the scope of this document and thus is not addressed
here.
4. For all stress imaging, the mode of stress testing is
assumed to be exercise (e.g., treadmill, bicycle) for
patients able to exercise. For patients unable to exercise,
it is assumed that dobutamine is used for echocardio-
graphic stress testing. Any indications requiring a
specific mode of stress (e.g., when hemodynamic infor-
mation is required) are labeled as such.
5. Doppler hemodynamic assessment during stress echo-
cardiography includes both right and left heart hemo-
dynamics (e.g., valvular gradients, pulmonary artery
pressure, mitral regurgitation severity).
6. The indications for the perioperative evaluation for
noncardiac surgery were modeled after the ACCF/
AHA guidelines on perioperative cardiovascular evalu-
ation and care for noncardiac surgery (16). If a patient
has signs/symptoms of suspected cardiac etiology, the
clinical scenario should be considered in the symptom-
atic category (e.g., Indication 1) and not in the periop-
erative section.
7. As with other surgeries, the need for coronary artery
disease (CAD) assessment prior to solid organ trans-
plantation is related to patient and surgical risk. In
general, solid organ transplantation should be consid-
ered in the vascular surgery category given that CAD is
common in patients with diabetes mellitus who have
end-stage renal disease.
4. Definitions
Definitions of terms used throughout the indication set are
listed here. Additional definitions are listed in Appendix A.
These definitions were provided to and discussed with the
technical panel prior to ratings of indications.
1. Ischemic Equivalent: Chest Pain Syndrome, Anginal
Equivalent, or Ischemic Electrocardiographic Abnor-
malities: Any constellation of clinical findings that the
physician feels is consistent with CAD. Examples ofsuch findings include, but are not limited to, chest pain,
chest tightness, chest burning, shoulder pain, palpita-
tions, jaw pain, new electrocardiographic abnormalities,
or other symptoms/findings suggestive of CAD. Nonchest
pain symptoms (e.g., dyspnea or reduced/worsening effort
tolerance) that are thought to be consistent with CAD may
also be considered to be an ischemic equivalent.
2. Global CAD Risk: It is assumed that clinicians will use
current standard methods of global risk assessment such
as those presented in the National Heart, Lung, and
Blood Institute report on Detection, Evaluation, and
Treatment of High Blood Cholesterol in Adults (Adult
Treatment Panel III [ATP III]) (18) or similar national
guidelines.
Absolute risk is defined as the probability of developing
CAD over a given time period. The ATP III report
specifies absolute risk for CAD over the next 10 years.
CAD risk refers to 10-year risk for any hard cardiac event
(e.g., myocardial infarction or CAD death). However,
acknowledging that global absolute risk scores may be
miscalibrated in certain populations (e.g., women, younger
men), clinical judgment must be applied in assigning
categorical risk thresholds in such subpopulations.
• Low global CAD risk
Defined by the age-specific risk level that is below
average. In general, low risk will correlate with a
10-year absolute CAD risk 10%. However, in
women and younger men, low risk may correlate with
10-year absolute CAD risk 6%.
• Intermediate global CAD risk
Defined by the age-specific risk level that is average. In
general, moderate risk will correlate with a 10-year
absolute CAD risk range of 10% to 20%. Among
women and younger age men, an expanded intermediate
risk range of 6% to 20% may be appropriate.
• High global CAD risk
Defined by the age-specific risk level that is above
average. In general, high risk will correlate with a
10-year absolute CAD risk of 20%. CAD equiva-
lents (e.g., diabetes mellitus, peripheral arterial dis-
ease) can also define high risk.
3. Pretest Probability of CAD: Symptomatic (Ischemic
Equivalent) Patients: Once the physician determines
that symptoms are present that may represent CAD, the
pretest probability of CAD should be assessed. There are
a number of risk algorithms (19,20) available that can be
used to calculate this probability. Clinicians should be
familiar with those algorithms that pertain to the popu-
lations they encounter most often. In scoring the indi-
cations, the following probabilities, as calculated from
any of the various available validated algorithms, should
be applied.
• Very low pretest probability: 5% pretest probabilityof CAD
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probability of CAD
• Intermediate pretest probability: Between 10% and
90% pretest probability of CAD
• High pretest probability:90% pretest probability of
CAD
The method recommended by the ACC/AHA guidelines
for chronic stable angina (21) is provided as one example of
a method used to calculate pretest probability and is a
modification of a previously published literature review (22).
Please refer to Table A and the definition of angina in
Appendix A. It is important to note that other historical
factors or electrocardiographic findings (e.g., prior infarc-
tion) can affect pretest probability, although these factors are
not accounted for in Table A. Similarly, although not
incorporated into the algorithm, other CAD risk factors
may also affect pretest likelihood of CAD. Detailed nomo-
grams are available that incorporate the effects of a history of
prior infarction, electrocardiographic Q waves and ST- and
T-wave changes, diabetes, smoking, and hypercholesterol-
emia (23).
5. Abbreviations
ACS  acute coronary syndrome
APC  atrial premature contraction
ABG  coronary artery bypass grafting surgery
CAD  coronary artery disease
CMR  cardiovascular magnetic resonance
CRT  cardiac resynchronization therapy
CT  computed tomography
ECG  electrocardiogram
HF  heart failure
ICD  implantable cardioverter-defibrillator
LBBB  left bundle-branch block
LV  left ventricular
MET  estimated metabolic equivalents of exercise
Table A. Pretest Probability of CAD by Age, Gender, and Symp
Age
(Years) Gender
Typical/Definite
Angina Pectoris
39 Men Intermediate
Women Intermediate
40–49 Men High
Women Intermediate
0–59 Men High
Women Intermediate
60 Men High
Women High
High: 90% pretest probability. Intermediate: Between 10% and 90% pretest probability. Low: Be
*Modified from the ACC/AHA Exercise Testing Guidelines (20a) to reflect all age ranges.MI  myocardial infarction dPCI  percutaneous coronary intervention
RNI  radionuclide imaging
SPECT MPI  single-photon emission computed
tomography myocardial perfusion imaging
STEMI  ST-segment elevation myocardial infarction
SVT  supraventricular tachycardia
TEE  transesophageal echocardiogram
TIA  transient ischemic attack
TIMI  Thrombolysis In Myocardial Infarction
TTE  transthoracic echocardiogram
UA/NSTEMI  unstable angina/non–ST-segment
elevation myocardial infarction
VPC  ventricular premature contraction
VT  ventricular tachycardia
6. Results of Ratings
The final ratings for echocardiography are listed by indica-
tion in Tables 1 to 18. The final score reflects the median
score of the 15 technical panel members and has been
labeled according to the 3 appropriate use categories of
appropriate (median 7 to 9), uncertain (median 4 to 6), and
inappropriate (median 1 to 3). Tables 19 to 21 present the
ndications by the appropriate use categories.
There was less variation in ratings for the indications
abeled as either appropriate or inappropriate, with 92% and
0%, respectively, showing agreement as defined in Meth-
ds Section 2. There was greater variability (less agreement)
n the rating scores for indications defined as uncertain, with
1% showing agreement as defined previously. Two indica-
ions, 182 and 189, were distributed into each extreme such
hat the panel was classified as being in disagreement.
owever, the median scores for these indications were
lready placed in the uncertain category, so no changes were
equired to reflect disagreement. Across all categories, 40
ndications did not meet the definition of agreement;
owever, the scores were not so divergent (as defined by
*
ypical/Probable
ngina Pectoris
Nonanginal
Chest Pain Asymptomatic
Intermediate Low Very low
Very low Very low Very low
Intermediate Intermediate Low
Low Very low Very low
Intermediate Intermediate Low
Intermediate Low Very low
Intermediate Intermediate Low
Intermediate Intermediate Low
5% and 10% pretest probability. Very low: 5% pretest probability.toms
At
Aisagreement) as to necessitate a change in the final score.
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Table 1. TTE for General Evaluation of Cardiac Structure and Function
Indication
Appropriate Use
Score (1–9)
Suspected Cardiac Etiology—General With TTE
1. ● Symptoms or conditions potentially related to suspected cardiac etiology including but not limited to chest
pain, shortness of breath, palpitations, TIA, stroke, or peripheral embolic event
A (9)
2. ● Prior testing that is concerning for heart disease or structural abnormality including but not limited to chest
X-ray, baseline scout images for stress echocardiogram, ECG, or cardiac biomarkers
A (9)
Arrhythmias With TTE
3. ● Infrequent APCs or infrequent VPCs without other evidence of heart disease I (2)
4. ● Frequent VPCs or exercise-induced VPCs A (8)
5. ● Sustained or nonsustained atrial fibrillation, SVT, or VT A (9)
6. ● Asymptomatic isolated sinus bradycardia I (2)
Lightheadedness/Presyncope/Syncope With TTE
7. ● Clinical symptoms or signs consistent with a cardiac diagnosis known to cause lightheadedness/presyncope/
syncope (including but not limited to aortic stenosis, hypertrophic cardiomyopathy, or HF)
A (9)
8. ● Lightheadedness/presyncope when there are no other symptoms or signs of cardiovascular disease I (3)
9. ● Syncope when there are no other symptoms or signs of cardiovascular disease A (7)
Evaluation of Ventricular Function With TTE
10. ● Initial evaluation of ventricular function (e.g., screening) with no symptoms or signs of cardiovascular disease I (2)
11. ● Routine surveillance of ventricular function with known CAD and no change in clinical status or cardiac exam I (3)
12. ● Evaluation of LV function with prior ventricular function evaluation showing normal function (e.g., prior
echocardiogram, left ventriculogram, CT, SPECT MPI, CMR) in patients in whom there has been no change in
clinical status or cardiac exam
I (1)
Perioperative Evaluation With TTE
13. ● Routine perioperative evaluation of ventricular function with no symptoms or signs of cardiovascular disease I (2)
14. ● Routine perioperative evaluation of cardiac structure and function prior to noncardiac solid organ
transplantation
U (6)
Pulmonary Hypertension With TTE
15. ● Evaluation of suspected pulmonary hypertension including evaluation of right ventricular function and
estimated pulmonary artery pressure
A (9)
16. ● Routine surveillance (1 y) of known pulmonary hypertension without change in clinical status or cardiac exam I (3)
17. ● Routine surveillance (1 y) of known pulmonary hypertension without change in clinical status or cardiac exam A (7)
18. ● Re-evaluation of known pulmonary hypertension if change in clinical status or cardiac exam or to guide therapy A (9)
A indicates appropriate; I, inappropriate; and U, uncertain.
Table 2. TTE for Cardiovascular Evaluation in an Acute Setting
Indication
Appropriate Use
Score (1–9)
Hypotension or Hemodynamic Instability With TTE
19. ● Hypotension or hemodynamic instability of uncertain or suspected cardiac etiology A (9)
20. ● Assessment of volume status in a critically ill patient U (5)
Myocardial Ischemia/Infarction With TTE
21. ● Acute chest pain with suspected MI and nondiagnostic ECG when a resting echocardiogram can be performed
during pain
A (9)
22. ● Evaluation of a patient without chest pain but with other features of an ischemic equivalent or laboratory
markers indicative of ongoing MI
A (8)
23. ● Suspected complication of myocardial ischemia/infarction, including but not limited to acute mitral
regurgitation, ventricular septal defect, free-wall rupture/tamponade, shock, right ventricular involvement, HF,
or thrombus
A (9)
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Indication
Appropriate Use
Score (1–9)
Evaluation of Ventricular Function after ACS With TTE
24. ● Initial evaluation of ventricular function following ACS A (9)
25. ● Re-evaluation of ventricular function following ACS during recovery phase when results will guide therapy A (9)
Respiratory Failure With TTE
26. ● Respiratory failure or hypoxemia of uncertain etiology A (8)
27. ● Respiratory failure or hypoxemia when a noncardiac etiology of respiratory failure has been established U (5)
Pulmonary Embolism With TTE
28. ● Suspected pulmonary embolism in order to establish diagnosis I (2)
29. ● Known acute pulmonary embolism to guide therapy (e.g., thrombectomy and thrombolytics) A (8)
30. ● Routine surveillance of prior pulmonary embolism with normal right ventricular function and pulmonary artery systolic
pressure
I (1)
31. ● Re-evaluation of known pulmonary embolism after thrombolysis or thrombectomy for assessment of change in right
ventricular function and/or pulmonary artery pressure
A (7)
Cardiac Trauma With TTE
32. ● Severe deceleration injury or chest trauma when valve injury, pericardial effusion, or cardiac injury are possible or
suspected
A (9)
33. ● Routine evaluation in the setting of mild chest trauma with no electrocardiographic changes or biomarker elevation I (2)A indicates appropriate; I, inappropriate; and U, uncertain.Table 3. TTE for Evaluation of Valvular Function
Indication
Appropriate Use
Score (1–9)
Murmur or Click With TTE
34. ● Initial evaluation when there is a reasonable suspicion of valvular or structural heart disease A (9)
35. ● Initial evaluation when there are no other symptoms or signs of valvular or structural heart disease I (2)
36. ● Re-evaluation in a patient without valvular disease on prior echocardiogram and no change in clinical status or
cardiac exam
I (1)
37. ● Re-evaluation of known valvular heart disease with a change in clinical status or cardiac exam or to guide
therapy
A (9)
Native Valvular Stenosis With TTE
38. ● Routine surveillance (3 y) of mild valvular stenosis without a change in clinical status or cardiac exam I (3)
39. ● Routine surveillance (3 y) of mild valvular stenosis without a change in clinical status or cardiac exam A (7)
40. ● Routine surveillance (1 y) of moderate or severe valvular stenosis without a change in clinical status or
cardiac exam
I (3)
41. ● Routine surveillance (1 y) of moderate or severe valvular stenosis without a change in clinical status or
cardiac exam
A (8)
Native Valvular Regurgitation With TTE
42. ● Routine surveillance of trace valvular regurgitation I (1)
43. ● Routine surveillance (3 y) of mild valvular regurgitation without a change in clinical status or cardiac exam I (2)
44. ● Routine surveillance (3 y) of mild valvular regurgitation without a change in clinical status or cardiac exam U (4)
45. ● Routine surveillance (1 y) of moderate or severe valvular regurgitation without a change in clinical status or
cardiac exam
U (6)
46. ● Routine surveillance (1 y) of moderate or severe valvular regurgitation without change in clinical status or
cardiac exam
A (8)
Prosthetic Valves With TTE
47. ● Initial postoperative evaluation of prosthetic valve for establishment of baseline A (9)
48. ● Routine surveillance (3 y after valve implantation) of prosthetic valve if no known or suspected valve
dysfunction
I (3)
49. ● Routine surveillance (3 y after valve implantation) of prosthetic valve if no known or suspected valve
dysfunction
A (7)
50. ● Evaluation of prosthetic valve with suspected dysfunction or a change in clinical status or cardiac exam A (9)
51. ● Re-evaluation of known prosthetic valve dysfunction when it would change management or guide therapy A (9)
1135JACC Vol. 57, No. 9, 2011 Douglas et al.
March 1, 2011:1126–66 Appropriate Use Criteria for EchocardiographyTable 3. Continued
Indication
Appropriate Use
Score (1–9)
Infective Endocarditis (Native or Prosthetic Valves) With TTE
52. ● Initial evaluation of suspected infective endocarditis with positive blood cultures or a new murmur A (9)
53. ● Transient fever without evidence of bacteremia or a new murmur I (2)
54. ● Transient bacteremia with a pathogen not typically associated with infective endocarditis and/or a documented
nonendovascular source of infection
I (3)
55. ● Re-evaluation of infective endocarditis at high risk for progression or complication or with a change in clinical status or
cardiac exam
A (9)
56. ● Routine surveillance of uncomplicated infective endocarditis when no change in management is contemplated I (2)A indicates appropriate; I, inappropriate; and U, uncertain.Table 4. TTE for Evaluation of Intracardiac and Extracardiac Structures and Chambers
Indication
Appropriate Use
Score (1–9)
57. ● Suspected cardiac mass A (9)
58. ● Suspected cardiovascular source of embolus A (9)
59. ● Suspected pericardial conditions A (9)
60. ● Routine surveillance of known small pericardial effusion with no change in clinical status I (2)
61. ● Re-evaluation of known pericardial effusion to guide management or therapy A (8)
62. ● Guidance of percutaneous noncoronary cardiac procedures including but not limited to pericardiocentesis,
septal ablation, or right ventricular biopsy
A (9)A indicates appropriate; and I, inappropriate.Table 5. TTE for Evaluation of Aortic Disease
Indication
Appropriate Use
Score (1–9)
63. ● Evaluation of the ascending aorta in the setting of a known or suspected connective tissue disease or genetic
condition that predisposes to aortic aneurysm or dissection (e.g., Marfan syndrome)
A (9)
64. ● Re-evaluation of known ascending aortic dilation or history of aortic dissection to establish a baseline rate of
expansion or when the rate of expansion is excessive
A (9)
65. ● Re-evaluation of known ascending aortic dilation or history of aortic dissection with a change in clinical status
or cardiac exam or when findings may alter management or therapy
A (9)
66. ● Routine re-evaluation for surveillance of known ascending aortic dilation or history of aortic dissection without a
change in clinical status or cardiac exam when findings would not change management or therapy
I (3)A indicates appropriate; and I, inappropriate.Table 6. TTE for Evaluation of Hypertension, HF, or Cardiomyopathy
Indication
Appropriate Use
Score (1–9)
Hypertension With TTE
67. ● Initial evaluation of suspected hypertensive heart disease A (8)
68. ● Routine evaluation of systemic hypertension without symptoms or signs of hypertensive heart disease I (3)
69. ● Re-evaluation of known hypertensive heart disease without a change in clinical status or cardiac exam U (4)
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Indication
Appropriate Use
Score (1–9)
HF With TTE
70. ● Initial evaluation of known or suspected HF (systolic or diastolic) based on symptoms, signs, or abnormal test results A (9)
71. ● Re-evaluation of known HF (systolic or diastolic) with a change in clinical status or cardiac exam without a clear
precipitating change in medication or diet
A (8)
72. ● Re-evaluation of known HF (systolic or diastolic) with a change in clinical status or cardiac exam with a clear
precipitating change in medication or diet
U (4)
73. ● Re-evaluation of known HF (systolic or diastolic) to guide therapy A (9)
74. ● Routine surveillance (1 y) of HF (systolic or diastolic) when there is no change in clinical status or cardiac exam I (2)
75. ● Routine surveillance (1 y) of HF (systolic or diastolic) when there is no change in clinical status or cardiac exam U (6)
Device Evaluation (Including Pacemaker, ICD, or CRT) With TTE
76. ● Initial evaluation or re-evaluation after revascularization and/or optimal medical therapy to determine candidacy for
device therapy and/or to determine optimal choice of device
A (9)
77. ● Initial evaluation for CRT device optimization after implantation U (6)
78. ● Known implanted pacing device with symptoms possibly due to device complication or suboptimal pacing device
settings
A (8)
79. ● Routine surveillance (1 y) of implanted device without a change in clinical status or cardiac exam I (1)
80. ● Routine surveillance (1 y) of implanted device without a change in clinical status or cardiac exam I (3)
Ventricular Assist Devices and Cardiac Transplantation With TTE
81. ● To determine candidacy for ventricular assist device A (9)
82. ● Optimization of ventricular assist device settings A (7)
83. ● Re-evaluation for signs/symptoms suggestive of ventricular assist device-related complications A (9)
84. ● Monitoring for rejection in a cardiac transplant recipient A (7)
85. ● Cardiac structure and function evaluation in a potential heart donor A (9)
Cardiomyopathies With TTE
86. ● Initial evaluation of known or suspected cardiomyopathy (e.g., restrictive, infiltrative, dilated, hypertrophic, or genetic
cardiomyopathy)
A (9)
87. ● Re-evaluation of known cardiomyopathy with a change in clinical status or cardiac exam or to guide therapy A (9)
88. ● Routine surveillance (1 y) of known cardiomyopathy without a change in clinical status or cardiac exam I (2)
89. ● Routine surveillance (1 y) of known cardiomyopathy without a change in clinical status or cardiac exam U (5)
90. ● Screening evaluation for structure and function in first-degree relatives of a patient with an inherited cardiomyopathy A (9)
91. ● Baseline and serial re-evaluations in a patient undergoing therapy with cardiotoxic agents A (9)A indicates appropriate; I, inappropriate; and U, uncertain.Table 7. TTE for Adult Congenital Heart Disease
Indication
Appropriate Use
Score (1–9)
92. ● Initial evaluation of known or suspected adult congenital heart disease A (9)
93. ● Known adult congenital heart disease with a change in clinical status or cardiac exam A (9)
94. ● Re-evaluation to guide therapy in known adult congenital heart disease A (9)
95. ● Routine surveillance (2 y) of adult congenital heart disease following complete repair
X without a residual structural or hemodynamic abnormality
X without a change in clinical status or cardiac exam
I (3)
96. ● Routine surveillance (2 y) of adult congenital heart disease following complete repair
X without residual structural or hemodynamic abnormality
X without a change in clinical status or cardiac exam
U (6)
97. ● Routine surveillance (1 y) of adult congenital heart disease following incomplete or palliative repair
X with residual structural or hemodynamic abnormality
X without a change in clinical status or cardiac exam
U (5)
98. ● Routine surveillance (1 y) of adult congenital heart disease following incomplete or palliative repair
X with residual structural or hemodynamic abnormality
X without a change in clinical status or cardiac exam
A (8)A indicates appropriate; I, inappropriate; and U, uncertain.
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Indication
Appropriate Use
Score (1–9)
TEE as Initial or Supplemental Test—General Uses
99. ● Use of TEE when there is a high likelihood of a nondiagnostic TTE due to patient characteristics or inadequate
visualization of relevant structures
A (8)
100. ● Routine use of TEE when a diagnostic TTE is reasonably anticipated to resolve all diagnostic and management
concerns
I (1)
101. ● Re-evaluation of prior TEE finding for interval change (e.g., resolution of thrombus after anticoagulation,
resolution of vegetation after antibiotic therapy) when a change in therapy is anticipated
A (8)
102. ● Surveillance of prior TEE finding for interval change (e.g., resolution of thrombus after anticoagulation,
resolution of vegetation after antibiotic therapy) when no change in therapy is anticipated
I (2)
103. ● Guidance during percutaneous noncoronary cardiac interventions including but not limited to closure device
placement, radiofrequency ablation, and percutaneous valve procedures
A (9)
104. ● Suspected acute aortic pathology including but not limited to dissection/transsection A (9)
105. ● Routine assessment of pulmonary veins in an asymptomatic patient status post pulmonary vein isolation I (3)
TEE as Initial or Supplemental Test—Valvular Disease
106. ● Evaluation of valvular structure and function to assess suitability for, and assist in planning of, an intervention A (9)
107. ● To diagnose infective endocarditis with a low pretest probability (e.g., transient fever, known alternative source
of infection, or negative blood cultures/atypical pathogen for endocarditis)
I (3)
108. ● To diagnose infective endocarditis with a moderate or high pretest probability (e.g., staph bacteremia,
fungemia, prosthetic heart valve, or intracardiac device)
A (9)
TEE as Initial or Supplemental Test—Embolic Event
109. ● Evaluation for cardiovascular source of embolus with no identified noncardiac source A (7)
110. ● Evaluation for cardiovascular source of embolus with a previously identified noncardiac source U (5)
111. ● Evaluation for cardiovascular source of embolus with a known cardiac source in which a TEE would not change
management
I (1)
TEE as Initial Test—Atrial Fibrillation/Flutter
112. ● Evaluation to facilitate clinical decision making with regard to anticoagulation, cardioversion, and/or
radiofrequency ablation
A (9)
113. ● Evaluation when a decision has been made to anticoagulate and not to perform cardioversion I (2)A indicates appropriate; I, inappropriate; and U, uncertain.Table 9. Stress Echocardiography for Detection of CAD/Risk Assessment: Symptomatic or Ischemic Equivalent
Indication
Appropriate Use
Score (1–9)
Evaluation of Ischemic Equivalent (Nonacute) With Stress Echocardiography
114. ● Low pretest probability of CAD
● ECG interpretable and able to exercise
I (3)
115. ● Low pretest probability of CAD
● ECG uninterpretable or unable to exercise
A (7)
116. ● Intermediate pretest probability of CAD
● ECG interpretable and able to exercise
A (7)
117. ● Intermediate pretest probability of CAD
● ECG uninterpretable or unable to exercise
A (9)
118. ● High pretest probability of CAD
● Regardless of ECG interpretability and ability to exercise
A (7)
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Indication
Appropriate Use
Score (1–9)
Acute Chest Pain With Stress Echocardiography
119. ● Possible ACS
● ECG: no ischemic changes or with LBBB or electronically paced ventricular rhythm
● Low-risk TIMI score
● Negative troponin levels
A (7)
120. ● Possible ACS
● ECG: no ischemic changes or with LBBB or electronically paced ventricular rhythm
● Low-risk TIMI score
● Peak troponin: borderline, equivocal, minimally elevated
A (7)
121. ● Possible ACS
● ECG: no ischemic changes or with LBBB or electronically paced ventricular rhythm
● High-risk TIMI score
● Negative troponin levels
A (7)
122. ● Possible ACS
● ECG: no ischemic changes or with LBBB or electronically paced ventricular rhythm
● High-risk TIMI score
● Peak troponin: borderline, equivocal, minimally elevated
A (7)
123. ● Definite ACS I (1)A indicates appropriate; and I, inappropriate.Table 10. Stress Echocardiography for Detection of CAD/Risk Assessment: Asymptomatic (Without Ischemic Equivalent)
Indication
Appropriate Use
Score (1–9)
General Patient Populations With Stress Echocardiography
124. ● Low global CAD risk I (1)
125. ● Intermediate global CAD risk
● ECG interpretable
I (2)
126. ● Intermediate global CAD risk
● ECG uninterpretable
U (5)
127. ● High global CAD risk U (5)I indicates inappropriate; and U, uncertain.Table 11. Stress Echocardiography for Detection of CAD/Risk Assessment: Asymptomatic (Without Ischemic Equivalent)
in Patient Populations With Defined Comorbidities
Indication
Appropriate Use
Score (1–9)
New-Onset or Newly Diagnosed HF or LV Systolic Dysfunction With Stress Echocardiography
128. ● No prior CAD evaluation and no planned coronary angiography A (7)
Arrhythmias With Stress Echocardiography
129. ● Sustained VT A (7)
130. ● Frequent PVCs, exercise induced VT, or nonsustained VT A (7)
131. ● Infrequent PVCs I (3)
132. ● New-onset atrial fibrillation U (6)
Syncope With Stress Echocardiography
133. ● Low global CAD risk I (3)
134. ● Intermediate or high global CAD risk A (7)
Elevated Troponin With Stress Echocardiography
135. ● Troponin elevation without symptoms or additional evidence of ACS A (7)A indicates appropriate; I, inappropriate; and U, uncertain.
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Indication
Appropriate Use
Score (1–9)
Asymptomatic: Prior Evidence of Subclinical Disease With Stress Echocardiography
136. ● Coronary calcium Agatston score 100 I (2)
137. ● Low to intermediate global CAD risk
● Coronary calcium Agatston score between 100 and 400
U (5)
138. ● High global CAD risk
● Coronary calcium Agatston score between 100 and 400
U (6)
139. ● Coronary calcium Agatston score 400 A (7)
140. ● Abnormal carotid intimal medial thickness (0.9 mm and/or the presence of plaque encroaching into the
arterial lumen)
U (5)
Coronary Angiography (Invasive or Noninvasive) With Stress Echocardiography
141. ● Coronary artery stenosis of unclear significance A (8)
Asymptomatic or Stable Symptoms With Stress Echocardiography
Normal Prior Stress Imaging Study
142. ● Low global CAD risk
● Last stress imaging study 2 y ago
I (1)
143. ● Low global CAD risk
● Last stress imaging study 2 y ago
I (2)
144. ● Intermediate to high global CAD risk
● Last stress imaging study 2 y ago
I (2)
145. ● Intermediate to high global CAD risk
● Last stress imaging study 2 y ago
U (4)
Asymptomatic or Stable Symptoms With Stress Echocardiography
Abnormal Coronary Angiography or Abnormal Prior Stress Study
No Prior Revascularization
146. ● Known CAD on coronary angiography or prior abnormal stress imaging study
● Last stress imaging study 2 y ago
I (3)
147. ● Known CAD on coronary angiography or prior abnormal stress imaging study
● Last stress imaging study 2 y ago
U (5)
Treadmill ECG Stress Test With Stress Echocardiography
148. ● Low-risk treadmill score (e.g., Duke) I (1)
149. ● Intermediate-risk treadmill score (e.g., Duke) A (7)
150. ● High-risk treadmill score (e.g., Duke) A (7)
New or Worsening Symptoms With Stress Echocardiography
151. ● Abnormal coronary angiography or abnormal prior stress imaging study A (7)
152. ● Normal coronary angiography or normal prior stress imaging study U (6)
Prior Noninvasive Evaluation With Stress Echocardiography
153. ● Equivocal, borderline, or discordant stress testing where obstructive CAD remains a concern A (8)A indicates appropriate; I, inappropriate; and U, uncertain.
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Without Active Cardiac Conditions
Indication
Appropriate Use
Score (1–9)
Low-Risk Surgery With Stress Echocardiography
154. ● Perioperative evaluation for risk assessment I (1)
Intermediate-Risk Surgery With Stress Echocardiography
155. ● Moderate to good functional capacity (4 METs) I (3)
156. ● No clinical risk factors I (2)
157. ● 1 clinical risk factor
● Poor or unknown functional capacity (4 METs)
U (6)
158. ● Asymptomatic 1 y post normal catheterization, noninvasive test, or previous revascularization I (1)
Vascular Surgery With Stress Echocardiography
159. ● Moderate to good functional capacity (4 METs) I (3)
160. ● No clinical risk factors I (2)
161. ● 1 clinical risk factor
● Poor or unknown functional capacity (4 METs)
A (7)
162. ● Asymptomatic 1 y post normal catheterization, noninvasive test, or previous revascularization I (2)A indicates appropriate; I, inappropriate; and U, uncertain.Table 14. Stress Echocardiography for Risk Assessment: Within 3 Months of an ACS
Indication
Appropriate Use
Score (1–9)
STEMI With Stress Echocardiography
163. ● Primary PCI with complete revascularization
● No recurrent symptoms
I (2)
164. ● Hemodynamically stable, no recurrent chest pain symptoms, or no signs of HF
● To evaluate for inducible ischemia
● No prior coronary angiography since the index event
A (7)
165. ● Hemodynamically unstable, signs of cardiogenic shock, or mechanical complications I (1)
UA/NSTEMI With Stress Echocardiography
166. ● Hemodynamically stable, no recurrent chest pain symptoms, or no signs of HF
● To evaluate for inducible ischemia
● No prior coronary angiography since the index event
A (8)
ACS—Asymptomatic Postrevascularization (PCI or CABG) With Stress Echocardiography
167. ● Prior to hospital discharge in a patient who has been adequately revascularized I (1)
Cardiac Rehabilitation With Stress Echocardiography
168. ● Prior to initiation of cardiac rehabilitation (as a stand-alone indication) I (3)A indicates appropriate; and I, inappropriate.Table 15. Stress Echocardiography for Risk Assessment: Postrevascularization (PCI or CABG)
Indication
Appropriate Use
Score (1–9)
Symptomatic With Stress Echocardiography
169. ● Ischemic equivalent A (8)
Asymptomatic With Stress Echocardiography
170. ● Incomplete revascularization
● Additional revascularization feasible
A (7)
171. ● 5 y after CABG I (2)
172. ● 5 y after CABG U (6)
173. ● 2 y after PCI I (2)
174. ● 2 y after PCI U (5)
Cardiac Rehabilitation With Stress Echocardiography
175. ● Prior to initiation of cardiac rehabilitation (as a stand-alone indication) I (3)A indicates appropriate; I, inappropriate; and U, uncertain.
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Indication
Appropriate Use
Score (1–9)
Ischemic Cardiomyopathy/Assessment of Viability With Stress Echocardiography
176. ● Known moderate or severe LV dysfunction
● Patient eligible for revascularization
● Use of dobutamine stress only
A (8)A indicates appropriate.Table 17. Stress Echocardiography for Hemodynamics (Includes Doppler During Stress)
Indication
Appropriate Use
Score (1–9)
Chronic Valvular Disease—Asymptomatic With Stress Echocardiography
177. ● Mild mitral stenosis I (2)
178. ● Moderate mitral stenosis U (5)
179. ● Severe mitral stenosis A (7)
180. ● Mild aortic stenosis I (3)
181. ● Moderate aortic stenosis U (6)
182. ● Severe aortic stenosis U (5)
183. ● Mild mitral regurgitation I (2)
184. ● Moderate mitral regurgitation U (5)
185. ● Severe mitral regurgitation
● LV size and function not meeting surgical criteria
A (7)
186. ● Mild aortic regurgitation I (2)
187. ● Moderate aortic regurgitation U (5)
188. ● Severe aortic regurgitation
● LV size and function not meeting surgical criteria
A (7)
Chronic Valvular Disease—Symptomatic With Stress Echocardiography
189. ● Mild mitral stenosis U (5)
190. ● Moderate mitral stenosis A (7)
191. ● Severe mitral stenosis I (3)
192. ● Severe aortic stenosis I (1)
193. ● Evaluation of equivocal aortic stenosis
● Evidence of low cardiac output or LV systolic dysfunction (“low gradient aortic stenosis”)
● Use of dobutamine only
A (8)
194. ● Mild mitral regurgitation U (4)
195. ● Moderate mitral regurgitation A (7)
196. ● Severe mitral regurgitation
● Severe LV enlargement or LV systolic dysfunction
I (3)
Acute Valvular Disease With Stress Echocardiography
197. ● Acute moderate or severe mitral or aortic regurgitation I (3)
Pulmonary Hypertension With Stress Echocardiography
198. ● Suspected pulmonary artery hypertension
● Normal or borderline elevated estimated right ventricular systolic pressure on resting echocardiographic study
U (5)
199. ● Routine evaluation of patients with known resting pulmonary hypertension I (3)
200. ● Re-evaluation of patient with exercise-induced pulmonary hypertension to evaluate response to therapy U (5)A indicates appropriate; I, inappropriate; and U, uncertain.Table 18. Contrast Use in TTE/TEE or Stress Echocardiography
Indication
Appropriate Use
Score (1–9)
201. ● Routine use of contrast
● All LV segments visualized on noncontrast images
I (1)
202. ● Selective use of contrast
● 2 contiguous LV segments are not seen on noncontrast images
A (8)A indicates appropriate; and I, inappropriate.
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Table 19. Appropriate Indications (Median Score 7–9)
Indication
Appropriate Use
Score (1–9)
TTE for General Evaluation of Cardiac Structure and Function
Suspected Cardiac Etiology—General
1. ● Symptoms or conditions potentially related to suspected cardiac etiology including but not limited to chest
pain, shortness of breath, palpitations, TIA, stroke, or peripheral embolic event
A (9)
2. ● Prior testing that is concerning for heart disease or structural abnormality including but not limited to chest
X-ray, baseline scout images for stress echocardiogram, ECG, or cardiac biomarkers
A (9)
TTE for General Evaluation of Cardiac Structure and Function
Arrhythmias
4. ● Frequent VPCs or exercise-induced VPCs A (8)
5. ● Sustained or nonsustained atrial fibrillation, SVT, or VT A (9)
TTE for General Evaluation of Cardiac Structure and Function
Lightheadedness/Presyncope/Syncope
7. ● Clinical symptoms or signs consistent with a cardiac diagnosis known to cause lightheadedness/presyncope/
syncope (including but not limited to aortic stenosis, hypertrophic cardiomyopathy, or HF)
A (9)
9. ● Syncope when there are no other symptoms or signs of cardiovascular disease A (7)
TTE for General Evaluation of Cardiac Structure and Function
Pulmonary Hypertension
15. ● Evaluation of suspected pulmonary hypertension including evaluation of right ventricular function and
estimated pulmonary artery pressure
A (9)
17. ● Routine surveillance (1 y) of known pulmonary hypertension without change in clinical status or cardiac exam A (7)
18. ● Re-evaluation of known pulmonary hypertension if change in clinical status or cardiac exam or to guide therapy A (9)
TTE for Cardiovascular Evaluation in an Acute Setting
Hypotension or Hemodynamic Instability
19. ● Hypotension or hemodynamic instability of uncertain or suspected cardiac etiology A (9)
TTE for Cardiovascular Evaluation in an Acute Setting
Myocardial Ischemia/Infarction
21. ● Acute chest pain with suspected MI and nondiagnostic ECG when a resting echocardiogram can be performed
during pain
A (9)
22. ● Evaluation of a patient without chest pain but with other features of an ischemic equivalent or laboratory
markers indicative of ongoing MI
A (8)
23. ● Suspected complication of myocardial ischemia/infarction, including but not limited to acute mitral
regurgitation, ventricular septal defect, free-wall rupture/tamponade, shock, right ventricular involvement, HF,
or thrombus
A (9)
TTE for Cardiovascular Evaluation in an Acute Setting
Evaluation of Ventricular Function After ACS
24. ● Initial evaluation of ventricular function following ACS A (9)
25. ● Re-evaluation of ventricular function following ACS during recovery phase when results will guide therapy A (9)
TTE for Cardiovascular Evaluation in an Acute Setting
Respiratory Failure
26. ● Respiratory failure or hypoxemia of uncertain etiology A (8)
TTE for Cardiovascular Evaluation in an Acute Setting
Pulmonary Embolism
29. ● Known acute pulmonary embolism to guide therapy (e.g., thrombectomy and thrombolytics) A (8)
31. ● Re-evaluation of known pulmonary embolism after thrombolysis or thrombectomy for assessment of change in
right ventricular function and/or pulmonary artery pressure
A (7)
TTE for Cardiovascular Evaluation in an Acute Setting
Cardiac Trauma
32. ● Severe deceleration injury or chest trauma when valve injury, pericardial effusion, or cardiac injury are possible
or suspected
A (9)
TTE for Evaluation of Valvular Function
Murmur or Click
34. ● Initial evaluation when there is a reasonable suspicion of valvular or structural heart disease A (9)
37. ● Re-evaluation of known valvular heart disease with a change in clinical status or cardiac exam or to guide
therapy
A (9)
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Indication
Appropriate Use
Score (1–9)
TTE for Evaluation of Valvular Function
Native Valvular Stenosis
39. ● Routine surveillance (3 y) of mild valvular stenosis without a change in clinical status or cardiac exam A (7)
41. ● Routine surveillance (1 y) of moderate or severe valvular stenosis without a change in clinical status or cardiac exam A (8)
46. ● Routine surveillance (1 y) of moderate or severe valvular regurgitation without change in clinical status or cardiac
exam
A (8)
TTE for Evaluation of Valvular Function
Prosthetic Valves
47. ● Initial postoperative evaluation of prosthetic valve for establishment of baseline A (9)
49. ● Routine surveillance (3 y after valve implantation) of prosthetic valve if no known or suspected valve dysfunction A (7)
50. ● Evaluation of prosthetic valve with suspected dysfunction or a change in clinical status or cardiac exam A (9)
51. ● Re-evaluation of known prosthetic valve dysfunction when it would change management or guide therapy A (9)
TTE for Evaluation of Valvular Function
Infective Endocarditis (Native or Prosthetic Valves)
52. ● Initial evaluation of suspected infective endocarditis with positive blood cultures or a new murmur A (9)
55. ● Re-evaluation of infective endocarditis at high risk for progression or complication or with a change in clinical status or
cardiac exam
A (9)
TTE for Evaluation of Intracardiac and Extracardiac Structures and Chambers
57. ● Suspected cardiac mass A (9)
58. ● Suspected cardiovascular source of embolus A (9)
59. ● Suspected pericardial conditions A (9)
61. ● Re-evaluation of known pericardial effusion to guide management or therapy A (8)
62. ● Guidance of percutaneous noncoronary cardiac procedures including but not limited to pericardiocentesis, septal
ablation, or right ventricular biopsy
A (9)
TTE for Evaluation of Aortic Disease
63. ● Evaluation of the ascending aorta in the setting of a known or suspected connective tissue disease or genetic condition
that predisposes to aortic aneurysm or dissection (e.g., Marfan syndrome)
A (9)
64. ● Re-evaluation of known ascending aortic dilation or history of aortic dissection to establish a baseline rate of
expansion or when the rate of expansion is excessive
A (9)
65. ● Re-evaluation of known ascending aortic dilation or history of aortic dissection with a change in clinical status or
cardiac exam or when findings may alter management or therapy
A (9)
TTE for Evaluation of Hypertension, HF, or Cardiomyopathy
Hypertension
67. ● Initial evaluation of suspected hypertensive heart disease A (8)
TTE for Evaluation of Hypertension, HF, or Cardiomyopathy
HF
70. ● Initial evaluation of known or suspected HF (systolic or diastolic) based on symptoms, signs, or abnormal test results A (9)
71. ● Re-evaluation of known HF (systolic or diastolic) with a change in clinical status or cardiac exam without a clear
precipitating change in medication or diet
A (8)
73. ● Re-evaluation of known HF (systolic or diastolic) to guide therapy A (9)
TTE for Evaluation of Hypertension, HF, or Cardiomyopathy
Device Evaluation (Including Pacemaker, ICD, or CRT)
76. ● Initial evaluation or re-evaluation after revascularization and/or optimal medical therapy to determine candidacy for
device therapy and/or to determine optimal choice of device
A (9)
78. ● Known implanted pacing device with symptoms possibly due to device complication or suboptimal pacing device
settings
A (8)
TTE for Evaluation of Hypertension, HF, or Cardiomyopathy
Ventricular Assist Devices and Cardiac Transplantation
81. ● To determine candidacy for ventricular assist device A (9)
82. ● Optimization of ventricular assist device settings A (7)
83. ● Re-evaluation for signs/symptoms suggestive of ventricular assist device-related complications A (9)
84. ● Monitoring for rejection in a cardiac transplant recipient A (7)
85. ● Cardiac structure and function evaluation in a potential heart donor A (9)
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Indication
Appropriate Use
Score (1–9)
TTE for Evaluation of Hypertension, HF, or Cardiomyopathy
Cardiomyopathies
86. ● Initial evaluation of known or suspected cardiomyopathy (e.g., restrictive, infiltrative, dilated, hypertrophic, or genetic
cardiomyopathy)
A (9)
87. ● Re-evaluation of known cardiomyopathy with a change in clinical status or cardiac exam or to guide therapy A (9)
90. ● Screening evaluation for structure and function in first-degree relatives of a patient with an inherited cardiomyopathy A (9)
91. ● Baseline and serial re-evaluations in a patient undergoing therapy with cardiotoxic agents A (9)
TTE for Adult Congenital Heart Disease
92. ● Initial evaluation of known or suspected adult congenital heart disease A (9)
93. ● Known adult congenital heart disease with a change in clinical status or cardiac exam A (9)
94. ● Re-evaluation to guide therapy in known adult congenital heart disease A (9)
98. ● Routine surveillance (1 y) of adult congenital heart disease following incomplete or palliative repair
X with residual structural or hemodynamic abnormality
X without a change in clinical status or cardiac exam
A (8)
TEE as Initial or Supplemental Test—General Uses
99. ● Use of TEE when there is a high likelihood of a nondiagnostic TTE due to patient characteristics or inadequate
visualization of relevant structures
A (8)
101. ● Re-evaluation of prior TEE finding for interval change (e.g., resolution of thrombus after anticoagulation, resolution of
vegetation after antibiotic therapy) when a change in therapy is anticipated
A (8)
103. ● Guidance during percutaneous noncoronary cardiac interventions including but not limited to closure device placement,
radiofrequency ablation, and percutaneous valve procedures
A (9)
104. ● Suspected acute aortic pathology including but not limited to dissection/transsection A (9)
TEE as Initial or Supplemental Test—Valvular Disease
106. ● Evaluation of valvular structure and function to assess suitability for, and assist in planning of, an intervention A (9)
108. ● To diagnose infective endocarditis with a moderate or high pretest probability (e.g., staph bacteremia, fungemia,
prosthetic heart valve, or intracardiac device)
A (9)
TEE as Initial or Supplemental Test—Embolic Event
109. ● Evaluation for cardiovascular source of embolus with no identified noncardiac source A (7)
TEE as Initial Test—Atrial Fibrillation/Flutter
112. ● Evaluation to facilitate clinical decision making with regards to anticoagulation, cardioversion, and/or radiofrequency
ablation
A (9)
Stress Echocardiography for Detection of CAD/Risk Assessment: Symptomatic or Ischemic Equivalent
Evaluation of Ischemic Equivalent (Nonacute)
115. ● Low pretest probability of CAD
● ECG uninterpretable or unable to exercise
A (7)
116. ● Intermediate pretest probability of CAD
● ECG interpretable and able to exercise
A (7)
117. ● Intermediate pretest probability of CAD
● ECG uninterpretable or unable to exercise
A (9)
118. ● High pretest probability of CAD
● Regardless of ECG interpretability and ability to exercise
A (7)
Stress Echocardiography for Detection of CAD/Risk Assessment: Symptomatic or Ischemic Equivalent
Acute Chest Pain
119. ● Possible ACS
● ECG: no ischemic changes or with LBBB or electronically paced ventricular rhythm
● Low-risk TIMI score
● Negative troponin levels
A (7)
120. ● Possible ACS
● ECG: no ischemic changes or with LBBB or electronically paced ventricular rhythm
● Low-risk TIMI score
● Peak troponin: borderline, equivocal, minimally elevated
A (7)
121. ● Possible ACS
● ECG: no ischemic changes or with LBBB or electronically paced ventricular rhythm
● High-risk TIMI score
● Negative troponin levels
A (7)
122. ● Possible ACS
● ECG: no ischemic changes or with LBBB or electronically paced ventricular rhythm
● High-risk TIMI score
● Peak troponin: borderline, equivocal, minimally elevated
A (7)
1145JACC Vol. 57, No. 9, 2011 Douglas et al.
March 1, 2011:1126–66 Appropriate Use Criteria for EchocardiographyTable 19. Continued
Indication
Appropriate Use
Score (1–9)
Stress Echocardiography for Detection of CAD/Risk Assessment: Asymptomatic
(Without Ischemic Equivalent) in Patient Populations With Defined Comorbidities
New-Onset or Newly Diagnosed HF or LV Systolic Dysfunction
128. ● No prior CAD evaluation and no planned coronary angiography A (7)
Stress Echocardiography for Detection of CAD/Risk Assessment: Asymptomatic
(Without Ischemic Equivalent) in Patient Populations With Defined Comorbidities
Arrhythmias
129. ● Sustained VT A (7)
130. ● Frequent PVCs, exercise-induced VT, or nonsustained VT A (7)
Stress Echocardiography for Detection of CAD/Risk Assessment: Asymptomatic
(Without Ischemic Equivalent) in Patient Populations With Defined Comorbidities
Syncope
134. ● Intermediate or high global CAD risk A (7)
Stress Echocardiography for Detection of CAD/Risk Assessment: Asymptomatic
(Without Ischemic Equivalent) in Patient Populations With Defined Comorbidities
Elevated Troponin
135. ● Troponin elevation without symptoms or additional evidence of ACS A (7)
Stress Echocardiography Following Prior Test Results
Asymptomatic: Prior Evidence of Subclinical Disease
139. ● Coronary calcium Agatston score 400 A (7)
Stress Echocardiography Following Prior Test Results
Coronary Angiography (Invasive or Noninvasive)
141. ● Coronary artery stenosis of unclear significance A (8)
Stress Echocardiography Following Prior Test Results
Treadmill ECG Stress Test
149. ● Intermediate-risk treadmill score (e.g., Duke) A (7)
150. ● High-risk treadmill score (e.g., Duke) A (7)
Stress Echocardiography Following Prior Test Results
New or Worsening Symptoms
151. ● Abnormal coronary angiography or abnormal prior stress imaging study A (7)
Stress Echocardiography Following Prior Test Results
Prior Noninvasive Evaluation
153. ● Equivocal, borderline, or discordant stress testing where obstructive CAD remains a concern A (8)
Stress Echocardiography for Risk Assessment:
Perioperative Evaluation for Noncardiac Surgery Without Active Cardiac Conditions
Vascular Surgery
161. ● 1 clinical risk factor
● Poor or unknown functional capacity (4 METs)
A (7)
Stress Echocardiography for Risk Assessment: Within 3 Months of an ACS
STEMI
164. ● Hemodynamically stable, no recurrent chest pain symptoms, or no signs of HF
● To evaluate for inducible ischemia
● No prior coronary angiography since the index event
A (7)
Stress Echocardiography for Risk Assessment: Within 3 Months of an ACS
UA/NSTEMI
166. ● Hemodynamically stable, no recurrent chest pain symptoms, or no signs of HF
● To evaluate for inducible ischemia
● No prior coronary angiography since the index event
A (8)
Stress Echocardiography for Risk Assessment: Postrevascularization (PCI or CABG)
Symptomatic
169. ● Ischemic equivalent A (8)
Stress Echocardiography for Risk Assessment: Postrevascularization (PCI or CABG)
Asymptomatic
170. ● Incomplete revascularization
● Additional revascularization feasible
A (7)
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Indication
Appropriate Use
Score (1–9)
Stress Echocardiography for Assessment of Viability/Ischemia
Ischemic Cardiomyopathy/Assessment of Viability
176. ● Known moderate or severe LV dysfunction
● Patient eligible for revascularization
● Use of dobutamine stress only
A (8)
Stress Echocardiography for Hemodynamics (Includes Doppler During Stress)
Chronic Valvular Disease—Asymptomatic
179. ● Severe mitral stenosis A (7)
185. ● Severe mitral regurgitation
● LV size and function not meeting surgical criteria
A (7)
188. ● Severe aortic regurgitation
● LV size and function not meeting surgical criteria
A (7)
Stress Echocardiography for Hemodynamics (Includes Doppler During Stress)
Chronic Valvular Disease—Symptomatic
190. ● Moderate mitral stenosis A (7)
193. ● Evaluation of equivocal aortic stenosis
● Evidence of low cardiac output or LV systolic dysfunction (“low gradient aortic stenosis”)
● Use of dobutamine only
A (8)
195. ● Moderate mitral regurgitation A (7)
Contrast Use in TTE/TEE or Stress Echocardiography
202. ● Selective use of contrast
● 2 contiguous LV segments are not seen on noncontrast images
A (8)A indicates appropriate.Table 20. Uncertain Indications (Median Score 4–6)
Indication
Appropriate Use
Score (1–9)
TTE for General Evaluation of Cardiac Structure and Function
Perioperative Evaluation
14. ● Routine perioperative evaluation of cardiac structure and function prior to noncardiac solid organ
transplantation
U (6)
TTE for Cardiovascular Evaluation in an Acute Setting
Hypotension or Hemodynamic Instability
20. ● Assessment of volume status in a critically ill patient U (5)
TTE for Cardiovascular Evaluation in an Acute Setting
Respiratory Failure
27. ● Respiratory failure or hypoxemia when a noncardiac etiology of respiratory failure has been established U (5)
TTE for Evaluation of Valvular Function
Native Valvular Regurgitation
44. ● Routine surveillance (3 y) of mild valvular regurgitation without a change in clinical status or cardiac exam U (4)
45. ● Routine surveillance (1 y) of moderate or severe valvular regurgitation without a change in clinical status or
cardiac exam
U (6)
TTE for Evaluation of Hypertension, HF, or Cardiomyopathy
Hypertension
69. ● Re-evaluation of known hypertensive heart disease without a change in clinical status or cardiac exam U (4)
TTE for Evaluation of Hypertension, HF, or Cardiomyopathy
HF
72. ● Re-evaluation of known HF (systolic or diastolic) with a change in clinical status or cardiac exam with a clear
precipitating change in medication or diet
U (4)
75. ● Routine surveillance (1 y) of HF (systolic or diastolic) when there is no change in clinical status or cardiac
exam
U (6)
TTE for Evaluation of Hypertension, HF, or Cardiomyopathy
Device Evaluation (Including Pacemaker, ICD, or CRT)
77. ● Initial evaluation for CRT device optimization after implantation U (6)
TTE for Evaluation of Hypertension, HF, or Cardiomyopathy
Cardiomyopathies
89. ● Routine surveillance (1 y) of known cardiomyopathy without a change in clinical status or cardiac exam U (5)
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Indication
Appropriate Use
Score (1–9)
TTE for Adult Congenital Heart Disease
96. ● Routine surveillance (2 y) of adult congenital heart disease following complete repair
X without residual structural or hemodynamic abnormality
X without a change in clinical status or cardiac exam
U (6)
97. ● Routine surveillance (1 y) of adult congenital heart disease following incomplete or palliative repair
X with residual structural or hemodynamic abnormality
X without a change in clinical status or cardiac exam
U (5)
TEE as Initial or Supplemental Test—Embolic Event
110. ● Evaluation for cardiovascular source of embolus with a previously identified noncardiac source U (5)
Stress Echocardiography for Detection of CAD/Risk Assessment: Asymptomatic (Without Ischemic Equivalent)
General Patient Populations
126. ● Intermediate global CAD risk
● ECG uninterpretable
U (5)
127. ● High global CAD risk U (5)
Stress Echocardiography for Detection of CAD/Risk Assessment: Asymptomatic
(Without Ischemic Equivalent) in Patient Populations With Defined Comorbidities
Arrhythmias
132. ● New-onset atrial fibrillation U (6)
Stress Echocardiography Following Prior Test Results
Asymptomatic: Prior Evidence of Subclinical Disease
137. ● Low to intermediate global CAD risk
● Coronary calcium Agatston score between 100 and 400
U (5)
138. ● High global CAD risk
● Coronary calcium Agatston score between 100 and 400
U (6)
140. ● Abnormal carotid intimal medial thickness (0.9 mm and/or the presence of plaque encroaching into the arterial
lumen)
U (5)
Stress Echocardiography Following Prior Test Results
Asymptomatic or Stable Symptoms
Normal Prior Stress Imaging Study
145. ● Intermediate to high global CAD risk
● Last stress imaging study 2 y ago
U (4)
Stress Echocardiography Following Prior Test Results
Asymptomatic or Stable Symptoms
Abnormal Coronary Angiography or Abnormal Prior Stress Study
No Prior Revascularization
147. ● Known CAD on coronary angiography or prior abnormal stress imaging study
● Last stress imaging study 2 y ago
U (5)
Stress Echocardiography Following Prior Test Results
New or Worsening Symptoms
152. ● Normal coronary angiography or normal prior stress imaging study U (6)
Stress Echocardiography for Risk Assessment:
Perioperative Evaluation for Noncardiac Surgery Without Active Cardiac Conditions
Intermediate-Risk Surgery
157. ● 1 clinical risk factor
● Poor or unknown functional capacity (4 METs)
U (6)
Stress Echocardiography for Risk Assessment: Postrevascularization (PCI or CABG)
Asymptomatic
172. ● 5 y after CABG U (6)
174. ● 2 y after PCI U (5)
Stress Echocardiography for Hemodynamics (Includes Doppler During Stress)
Chronic Valvular Disease—Asymptomatic
178. ● Moderate mitral stenosis U (5)
181. ● Moderate aortic stenosis U (6)
182. ● Severe aortic stenosis U (5)
184. ● Moderate mitral regurgitation U (5)
187. ● Moderate aortic regurgitation U (5)
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Indication
Appropriate Use
Score (1–9)
Stress Echocardiography for Hemodynamics (Includes Doppler During Stress)
Chronic Valvular Disease—Symptomatic
189. ● Mild mitral stenosis U (5)
194. ● Mild mitral regurgitation U (4)
Stress Echocardiography for Hemodynamics (Includes Doppler During Stress)
Pulmonary Hypertension
198. ● Suspected pulmonary hypertension
● Normal or borderline elevated estimated right ventricular systolic pressure on resting echocardiographic study
U (5)
200. ● Re-evaluation of patient with exercise-induced pulmonary hypertension to evaluate response to therapy U (5)U indicates uncertain.
Table 21. Inappropriate Indications (Median Score 1–3)
Indication
Appropriate Use
Score (1–9)
TTE for General Evaluation of Cardiac Structure and Function
Arrhythmias
3. ● Infrequent APCs or infrequent VPCs without other evidence of heart disease I (2)
6. ● Asymptomatic isolated sinus bradycardia I (2)
TTE for General Evaluation of Cardiac Structure and Function
Lightheadedness/Presyncope/Syncope
8. ● Lightheadedness/presyncope when there are no other symptoms or signs of cardiovascular disease I (3)
TTE for General Evaluation of Cardiac Structure and Function
Evaluation of Ventricular Function
10. ● Initial evaluation of ventricular function (e.g., screening) with no symptoms or signs of cardiovascular disease I (2)
11. ● Routine surveillance of ventricular function with known CAD and no change in clinical status or cardiac exam I (3)
12. ● Evaluation of LV function with prior ventricular function evaluation showing normal function (e.g., prior
echocardiogram, left ventriculogram, CT, SPECT MPI, CMR) in patients in whom there has been no change in
clinical status or cardiac exam
I (1)
TTE for General Evaluation of Cardiac Structure and Function
Perioperative Evaluation
13. ● Routine perioperative evaluation of ventricular function with no symptoms or signs of cardiovascular disease I (2)
TTE for General Evaluation of Cardiac Structure and Function
Pulmonary Hypertension
16. ● Routine surveillance (1 y) of known pulmonary hypertension without change in clinical status or cardiac exam I (3)
TTE for Cardiovascular Evaluation in an Acute Setting
Pulmonary Embolism
28. ● Suspected pulmonary embolism in order to establish diagnosis I (2)
30. ● Routine surveillance of prior pulmonary embolism with normal right ventricular function and pulmonary artery
systolic pressure
I (1)
TTE for Cardiovascular Evaluation in an Acute Setting
Cardiac Trauma
33. ● Routine evaluation in the setting of mild chest trauma with no electrocardiographic changes or biomarker
elevation
I (2)
TTE for Evaluation of Valvular Function
Murmur or Click
35. ● Initial evaluation when there are no other symptoms or signs of valvular or structural heart disease I (2)
36. ● Re-evaluation in a patient without valvular disease on prior echocardiogram and no change in clinical status or
cardiac exam
I (1)
TTE for Evaluation of Valvular Function
Native Valvular Stenosis
38. ● Routine surveillance (3 y) of mild valvular stenosis without a change in clinical status or cardiac exam I (3)
40. ● Routine surveillance (1 y) of moderate or severe valvular stenosis without a change in clinical status or
cardiac exam
I (3)
TTE for Evaluation of Valvular Function
Native Valvular Regurgitation
42. ● Routine surveillance of trace valvular regurgitation I (1)
43. ● Routine surveillance (3 y) of mild valvular regurgitation without a change in clinical status or cardiac exam I (2)
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TTE for Evaluation of Valvular Function
Prosthetic Valves
48. ● Routine surveillance (3 y after valve implantation) of prosthetic valve if no known or suspected valve dysfunction I (3)
TTE for Evaluation of Valvular Function
Infective Endocarditis (Native or Prosthetic Valves)
53. ● Transient fever without evidence of bacteremia or a new murmur I (2)
54. ● Transient bacteremia with a pathogen not typically associated with infective endocarditis and/or a documented
nonendovascular source of infection
I (3)
56. ● Routine surveillance of uncomplicated infective endocarditis when no change in management is contemplated I (2)
TTE for Evaluation of Intracardiac and Extracardiac Structures and Chambers
60. ● Routine surveillance of known small pericardial effusion with no change in clinical status I (2)
TTE for Evaluation of Aortic Disease
66. ● Routine re-evaluation for surveillance of known ascending aortic dilation or history of aortic dissection without a
change in clinical status or cardiac exam when findings would not change management or therapy
I (3)
TTE for Evaluation of Hypertension, HF, or Cardiomyopathy
Hypertension
68. ● Routine evaluation of systemic hypertension without symptoms or signs of hypertensive heart disease I (3)
TTE for Evaluation of Hypertension, HF, or Cardiomyopathy
HF
74. ● Routine surveillance (1 y) of HF (systolic or diastolic) when there is no change in clinical status or cardiac exam I (2)
TTE for Evaluation of Hypertension, HF, or Cardiomyopathy
Device Evaluation (Including Pacemaker, ICD, or CRT)
79. ● Routine surveillance (1 y) of implanted device without a change in clinical status or cardiac exam I (1)
80. ● Routine surveillance (1 y) of implanted device without a change in clinical status or cardiac exam I (3)
TTE for Evaluation of Hypertension, HF, or Cardiomyopathy
Cardiomyopathies
88. ● Routine surveillance (1 y) of known cardiomyopathy without a change in clinical status or cardiac exam I (2)
TTE for Adult Congenital Heart Disease
95. ● Routine surveillance (2 y) of adult congenital heart disease following complete repair
X without a residual structural or hemodynamic abnormality
X without a change in clinical status or cardiac exam
I (3)
TEE as Initial or Supplemental Test—General Uses
100. ● Routine use of TEE when a diagnostic TTE is reasonably anticipated to resolve all diagnostic and management
concerns
I (1)
102. ● Surveillance of prior TEE finding for interval change (e.g., resolution of thrombus after anticoagulation, resolution of
vegetation after antibiotic therapy) when no change in therapy is anticipated
I (2)
105. ● Routine assessment of pulmonary veins in an asymptomatic patient status post pulmonary vein isolation I (3)
TEE as Initial or Supplemental Test—Valvular Disease
107. ● To diagnose infective endocarditis with a low pretest probability (e.g., transient fever, known alternative source of
infection, or negative blood cultures/atypical pathogen for endocarditis)
I (3)
TEE as Initial or Supplemental Test—Embolic Event
111. ● Evaluation for cardiovascular source of embolus with a known cardiac source in which a TEE would not change
management
I (1)
TEE as Initial Test—Atrial Fibrillation/Flutter
113. ● Evaluation when a decision has been made to anticoagulate and not to perform cardioversion I (2)
Stress Echocardiography for Detection of CAD/Risk Assessment: Symptomatic or Ischemic Equivalent
Evaluation of Ischemic Equivalent (Nonacute)
114. ● Low pretest probability of CAD
● ECG interpretable and able to exercise
I (3)
Stress Echocardiography for Detection of CAD/Risk Assessment: Symptomatic or Ischemic Equivalent
Acute Chest Pain
123. ● Definite ACS I (1)
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Indication
Appropriate Use
Score (1–9)
Stress Echocardiography for Detection of CAD/Risk Assessment: Asymptomatic (Without Ischemic Equivalent)
General Patient Populations
124. ● Low global CAD risk I (1)
125. ● Intermediate global CAD risk
● ECG interpretable
I (2)
Stress Echocardiography for Detection of CAD/Risk Assessment: Asymptomatic (Without Ischemic Equivalent)
in Patient Populations With Defined Comorbidities
Arrhythmias
131. ● Infrequent PVCs I (3)
Stress Echocardiography for Detection of CAD/Risk Assessment: Asymptomatic (Without Ischemic Equivalent)
in Patient Populations With Defined Comorbidities
Syncope
133. ● Low global CAD risk I (3)
Stress Echocardiography Following Prior Test Results
Asymptomatic: Prior Evidence of Subclinical Disease
136. ● Coronary calcium Agatston score 100 I (2)
Stress Echocardiography Following Prior Test Results
Asymptomatic or Stable Symptoms
Normal Prior Stress Imaging Study
142. ● Low global CAD risk
● Last stress imaging study 2 y ago
I (1)
143. ● Low global CAD risk
● Last stress imaging study 2 y ago
I (2)
144. ● Intermediate to high global CAD risk
● Last stress imaging study 2 y ago
I (2)
Stress Echocardiography Following Prior Test Results
Asymptomatic or Stable Symptoms
Abnormal Coronary Angiography or Abnormal Prior Stress Study
No Prior Revascularization
146. ● Known CAD on coronary angiography or prior abnormal stress imaging study
● Last stress imaging study 2 y ago
I (3)
Stress Echocardiography Following Prior Test Results
Treadmill ECG Stress Test
148. ● Low-risk treadmill score (e.g., Duke) I (1)
Stress Echocardiography for Risk Assessment: Perioperative Evaluation for Noncardiac Surgery Without Active Cardiac Conditions
Low-Risk Surgery
154. ● Perioperative evaluation for risk assessment I (1)
Stress Echocardiography for Risk Assessment: Perioperative Evaluation for Noncardiac Surgery Without Active Cardiac Conditions
Intermediate-Risk Surgery
155. ● Moderate to good functional capacity (4 METs) I (3)
156. ● No clinical risk factors I (2)
158. ● Asymptomatic 1 y post normal catheterization, noninvasive test, or previous revascularization I (1)
Stress Echocardiography for Risk Assessment: Perioperative Evaluation for Noncardiac Surgery Without Active Cardiac Conditions
Vascular Surgery
159. ● Moderate to good functional capacity (4 METs) I (3)
160. ● No clinical risk factors I (2)
162. ● Asymptomatic 1 y post normal catheterization, noninvasive test, or previous revascularization I (2)
Stress Echocardiography for Risk Assessment: Within 3 Months of an ACS
STEMI
163. ● Primary PCI with complete revascularization
● No recurrent symptoms
I (2)
165. ● Hemodynamically unstable, signs of cardiogenic shock, or mechanical complications I (1)
Stress Echocardiography for Risk Assessment: Within 3 Months of an ACS
ACS—Asymptomatic Postrevascularization (PCI or CABG)
167. ● Prior to hospital discharge in a patient who has been adequately revascularized I (1)
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Selected flow diagrams for several categories of indications are included here (Figs. 1 to 6).
Figure 1. Stress Echocardiography for Detection of CAD/Risk Assessment: Symptomatic or Ischemic Equivalent
Table 21. Continued
Indication
Appropriate Use
Score (1–9)
Stress Echocardiography for Risk Assessment: Within 3 Months of an ACS
Cardiac Rehabilitation
168. ● Prior to initiation of cardiac rehabilitation (as a stand-alone indication) I (3)
Stress Echocardiography for Risk Assessment: Postrevascularization (PCI or CABG)
Asymptomatic
171. ● 5 y after CABG I (2)
173. ● 2 y after PCI I (2)
Stress Echocardiography for Risk Assessment: Postrevascularization (PCI or CABG)
Cardiac Rehabilitation
175. ● Prior to initiation of cardiac rehabilitation (as a stand-alone indication) I (3)
Stress Echocardiography for Hemodynamics (Includes Doppler During Stress)
Chronic Valvular Disease—Asymptomatic
177. ● Mild mitral stenosis I (2)
180. ● Mild aortic stenosis I (3)
183. ● Mild mitral regurgitation I (2)
186. ● Mild aortic regurgitation I (2)
Stress Echocardiography for Hemodynamics (Includes Doppler During Stress)
Chronic Valvular Disease—Symptomatic
191. ● Severe mitral stenosis I (3)
192. ● Severe aortic stenosis I (1)
196. ● Severe mitral regurgitation
● Severe LV enlargement or LV systolic dysfunction
I (3)
Stress Echocardiography for Hemodynamics (Includes Doppler During Stress)
Acute Valvular disease
197. ● Acute moderate or severe mitral or aortic regurgitation I (3)
Stress Echocardiography for Hemodynamics (Includes Doppler During Stress)
Pulmonary Hypertension
199. ● Routine evaluation of patients with known resting pulmonary hypertension I (3)
Contrast Use in TTE/TEE or Stress Echocardiography
201. ● Routine use of contrast
● All LV segments visualized on noncontrast images
I (1)
I indicates inappropriate.
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Appropriate use criteria define patient subgroups where the
available medical evidence supplemented by expert opinion
are combined to assess whether the net benefit or risks of a
test or procedure make it reasonable to perform testing (in
this document, echocardiography) in a particular clinical
situation. The intent of these criteria is to guide the rational
use of a procedure, namely avoidance of either under- or
over-utilization, and thereby lead to improved outcomes,
more optimal healthcare delivery, and justifiable healthcare
expenditures.
This document is a revision and combination of the
original AUC for transthoracic and transesophageal echo-
cardiography (1) and stress echocardiography (2). The
revision adds insight provided by interim clinical data and
standards documents recently published in the literature and
clarifies areas in which omissions or lack of clarity existed in
the original criteria. Additionally, since publication of the
original AUC, several studies have assessed the application
of these criteria in clinical practice; results from these studies
were incorporated into this revision and will be briefly
summarized here.
Implementation Studies
Application of the 2007 AUC for TTE has been evalu-
ated at academic medical centers (22,24 –26), in Veterans
Affairs (VA) hospitals (27), and in community settings
(28,29). Several common themes deserve emphasis. First,
the majority of clinical scenarios for which TTEs were
Figure 6. Stress Echocardiography for Risk Assessment—Postordered were captured by AUC indications (11% to 16%of TTEs were unclassified) (24,27). Second, across the
implementation studies, there are remarkably similar
rates of appropriate and inappropriate use of TTE.
Among those TTEs with an indication addressed by the
AUC (thus removing unclassifiable patients), the major-
ity were rated as appropriate (87% to 91%) and the rate of
inappropriate TTEs was consistently low (9% to 13%)
(24 –27). In 1 study of outpatient TTEs (29), the rate of
appropriate TTEs was lower (74%), although this may be
attributable to a higher proportion of unclassified studies
in the outpatient setting, a pattern that has been observed
by others (24,26). The presence of a greater proportion of
unclassified TTEs in the outpatient setting might be
expected given that many of the indications in the
original AUC (1) specifically address symptoms or a
“change in clinical status.”
The most common appropriate indications for TTE
included initial evaluation of symptoms potentially caused
by suspected cardiac etiology, prior testing concerning for
heart disease, evaluation of valvular disease, and evaluation
of a heart failure indication (24) and are repeated in this
revision as Indications 1, 2, 34, and 70. Recommendations
for expanding the AUC related to addressing 1) perioper-
ative evaluation (Indications 13 and 14); 2) timing of follow
up for valvular heart disease (Indications 38 to 41 and 43 to
49); 3) assessment for device therapy (Indications 76 to 83);
and 4) use in some specialized care or “niche” programs
(e.g., solid organ transplantation) (Indications 14, 84, and
85), and these scenarios were included in the current
cularization (PCI or CABG)revasdocument. Finally, more indications reflecting outpatient
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added.
Studies evaluating the application of AUC for TEE had
similar results, with the vast majority of classifiable TEEs
being ordered for appropriate indications (94% to 97%) and
a smaller number not being classified by the AUC (6% to
9%) (30–32). The fact that the operator is more intimately
involved in the decision to perform TEE may help to
explain the higher appropriate use rate of TEE compared
with TTE. The most common indication for an initial TEE
was to guide anticoagulation decisions in patients with atrial
fibrillation or flutter (Indications 112 and 113) (30,31).
Recommendations for revision focused on refinement of the
indications for evaluation of cardiovascular source of em-
bolus (Indications 109 to 111).
Fewer studies have focused on the clinical application of
AUC for stress echocardiography (33,34). In 1 study, 19%
of stress echocardiograms could not be classified by the
AUC (33). Of the echocardiograms that were classified,
66% were for appropriate indications. The majority of
unclassified studies were centered in 2 areas: perioperative
risk assessment and risk assessment with prior test results. In
another study, 88% (n253) of stress echocardiograms were
ordered for indications outlined in the AUC, whereas 12%
(n36) were ordered for indications not addressed by the
AUC (34). Of the 253 studies for which the AUC docu-
ment could be applied, 71% (n180) studies were appro-
priate, 9% (n23) were uncertain, and 20% (n50) were
inappropriate studies.
The results of the implementation studies demonstrate
that the rate of inappropriate use of echocardiography is
similar in various regions of the United States. In
contrast, other studies of resource utilization have docu-
mented regional differences in utilization patterns (35). A
recent study (36) suggests that a substantial amount of
the observed geographic variability in use is attributable
to corresponding regional differences in patient health, a
conclusion supported by the AUC implementation data
which, unlike claims data, inherently address clinical
status. Further application of AUC may help to dissect
the true variations in care delivery by supplementing
claims data with clinical data; however, this warrants
further study.
In summary, studies evaluating clinical application of
AUC for echocardiography suggest that the majority of
clinical scenarios could be classified by the criteria and that
the majority of studies were ordered for appropriate indica-
tions. Further, the studies identified gaps in the AUC, likely
due to both omissions in the initial criteria and subsequent
advances in specialized care, which were of substantial
utility in guiding the revision process. Although improved,
we do not expect this AUC document to be all-inclusive of
the wide breadth of all possible clinical scenarios. Although
the results from the implementation studies indicate that
the original AUC for echocardiography were successful,they also support the need for the current update and
revision of the criteria.
Other Features of the Revision
In addition to incorporating the results from implementa-
tion studies, several other aspects of the revision deserve
emphasis. First, the revised document combines TTE,
TEE, and stress echocardiography, whereas the initial TTE
and TEE AUC (1) were published separately from the
stress echocardiography AUC (2). The indication tables still
focus on each modality separately, for example, TTE (or
TEE as an adjunct if TTE nondiagnostic), TEE as an
initial test, and stress echocardiography. The exception is
the final table (Table 18, Indications 201 and 202), which
covers contrast use and is applicable to all of the echocar-
diographic modalities. Second, a new table was created to
cover indications related to patients with adult congenital
heart disease, as this patient population is being encoun-
tered with greater frequency by adult cardiologists (Table 7,
Indications 92 to 98) (37). It should be noted that, with the
exception of some adults with ligated or occluded patent
ductus arteriosus (covered in Indications 95 and 96), most
congenital heart conditions have the potential for residual
anatomic or physiologic abnormalities, so that, even for
many asymptomatic and stable patients, an echocardiogram
will be considered to guide therapeutic decision making
rather than for routine surveillance. Third, existing tables
were expanded to be more comprehensive in covering
various clinical situations. Fourth, efforts were made to
address clinical scenarios that have recently been addressed
in revised or new practice guidelines, such as valvular heart
disease (14), perioperative evaluation (16), and evaluation of
thoracic aortic disease (38). The goal of relating indications
to the available evidence base was a consistent feature during
the revision process (see Online Appendix). If randomized
trials or practice guidelines relevant to indications were not
available, clinical scenarios addressed in expert consensus
documents were identified whenever possible. Finally, indi-
cations were added to better address evolving therapeutic
options such as CRT (Indications 76 to 78) or treatment/
follow-up of pulmonary hypertension (Indications 15 to 18).
An important focus during the revision process was to
harmonize the indications across noninvasive modalities,
such that the wording of the indications is identical with
other AUC criteria (3) whenever feasible. For echocardiog-
raphy, harmonization with other documents was most
relevant for the stress echocardiography portion. For in-
stance, Table 13, which addresses the perioperative assess-
ment for noncardiac surgery, mirrors Table 4 in the RNI
document (3). This should facilitate clinical application of
the criteria and assist the process of future revisions and
possibly the development of a multimodality imaging AUC
document.
Stress echocardiography tests, like many imaging tests,
may provide additional useful information beyond the
primary purpose outlined by the indication. In addition,
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However, the AUC for stress echocardiography were not
developed to quantify the incremental information or other
test characteristics beyond addressing the diagnostic need
inherent in an individual indication.
In ranking indications, panelists were asked to not con-
sider comparisons to other imaging procedures while com-
pleting their rankings. Nevertheless, stress echocardiogra-
phy and SPECT MPI have similar bodies of evidence to
support their use. Therefore, it is not surprising that the
overwhelming majority of final ratings of stress echocardi-
ography and stress RNI were concordant for similar clinical
indications. However, a small number of the final scores and
rating categories reported in this document differ from those
previously published for stress RNI (3). Specifically, 4
indications (Indications 127, 157, 171, and 172) were rated
differently. It is noteworthy that of these 4 indications, 3
also appeared in the first stress echocardiography AUC (2),
and all 3 indications were rated similarly in this revision,
requiring consistency in ratings across the 2 technical panels
composed of different individuals. The difference in the
rating for Indication 127 may have been directly affected by
publication of the DIAD study (39), which was not avail-
able at the time of the RNI ratings. Additionally, although
the final rankings were different from the RNI ratings,
Indications 127 and 171 demonstrated agreement within
the current echocardiography technical panel. Therefore,
the several indications with ratings that differed from RNI
may reflect new literature that has become available since
publication of the SPECT appropriateness criteria and
differences in the composition of the 2 panels.
Readers should also note that the categorical summaries
tend to accentuate differences that sometimes are slight. For
example, small fluctuations in a median rating (e.g., 4 versus
3) will cause an indication to switch appropriateness cate-
gories (e.g., from uncertain to inappropriate). This phenom-
enon was relevant for Indication 157, which was rated as
uncertain (median score 6) in this document, while the same
indication in the RNI document (corresponding Indication
43) was rated appropriate (median score 7). The most likely
reason for this is a simple variation in rating by the different
panel members, whether because of composition, different
levels of clinical experience, publication of additional liter-
ature, or different interpretations of data. The AUC Task
Force has carefully examined the issue of panel membership
and made every effort to ensure similar composition for each
panel. The RAND process has documented that the inter-
pretation of the literature by different sets of experts can
yield slightly different final ratings (6).
As described in the Methods section, within each main
disease category, a standardized approach was used in order
to capture the majority of clinical scenarios without making
the list of indications excessive. The approach was to create
5 broad clinical scenarios: 1) for initial diagnosis; 2) to guide
therapy or management, regardless of symptom status; 3) to
evaluate a change in clinical status or cardiac exam; 4) forearly follow-up without change in clinical status; and 5) for
late follow-up without change in clinical status. It should be
noted that many cardiovascular conditions have the poten-
tial for residual anatomic or physiologic abnormalities, so
that the timing and follow-up use of echocardiographic
imaging depends on the patient’s clinical status and the
magnitude of or risk for residual abnormalities. Thus,
routine surveillance indications for echocardiograms should
not apply in those situations in which there has been a
change in status or where an echocardiogram is being
considered to guide therapeutic decision making. For
asymptomatic or stable patients with known or suspected
residual anatomic or physiologic abnormalities, the timing
of the follow-up for considering changes in therapy in
patients should be determined by individual patient factors,
and not by the suggested intervals for routine surveillance
studies.
Overall, indications focusing on initial diagnosis, guid-
ance of therapy, or evaluation of a change in clinical status
were viewed favorably by the rating panel. Uncertain or
inappropriate ratings were more likely given to early rather
than late follow-up, especially for those indications when
the optimal interval of follow-up for asymptomatic patients
is uncertain. Whenever possible, indications for timing of
follow-up attempted to follow practice guidelines (14),
although for many indications, the most appropriate
follow-up interval for asymptomatic patients is not well
established. For this reason, as well as for clinical expedi-
ency, the follow-up interval selected is not meant to be rigid
but rather to represent an approximate time interval.
Although the overall approach was broad and inclusive,
certain specific clinical scenarios warranted focused indica-
tions based on results from the previously mentioned
implementation studies. Examples include Indications 71
and 72, which differentiate the re-evaluation of decompen-
sated heart failure when there is no clear precipitating
change in medication or diet versus when there is a clear
precipitating factor. In the setting of an obvious change in
diet or medication, a trial of appropriate medical therapy
and monitoring for clinical improvement may be justified
prior to ordering a repeat imaging test for assessment of
cardiac function (25). As such, Indication 72 (clear precip-
itating change in medication or diet) was rated as uncertain,
and Indication 71 was rated as appropriate. Another focused
clinical situation is reflected in Indication 76, “Initial eval-
uation or re-evaluation after revascularization and/or opti-
mal medical therapy to determine candidacy for device
therapy and/or to determine optimal choice of device.” As
per the results of an implementation study (24), this clinical
scenario was not well captured in the initial AUC docu-
ment. However, re-evaluation of LV ejection fraction after
revascularization or after a period of medical therapy to
determine device candidacy represents a standard of care
(40) and is a common indication for a TTE. This is now
represented by Indication 76, which was rated as appropriate.
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as common scenarios and now included are bradycardia
(Indication 6) and a new subcategory within TTE for the
evaluation of syncope (Indications 7 to 9). Additionally, the
sections on valvular heart disease (both resting TTE/TEE
and stress echocardiography for hemodynamics) have been
expanded in an effort to address a greater number of clinical
scenarios, and closely follow recent guideline recommenda-
tions (14).
Despite these extensive revisions and additions, all po-
tential clinical scenarios were not covered by the revised
AUC for echocardiography. Additionally, certain recom-
mendations from implementation studies were considered
to represent rare conditions or specialized practices and were
therefore not included in the revised document. If certain
clinical situations that are not currently covered are found to
be more frequent than anticipated, they will be incorporated
into future revisions. This emphasizes the iterative nature of
this process.
Furthermore, there are several general categories that
were purposefully not addressed. For example, intraopera-
tive use of TEE for cardiac surgery was felt to be beyond the
scope of this document. More highly specialized echocar-
diographic techniques, such as 3-dimensional echocardiog-
raphy or epicardial imaging, are not addressed in this
document. Additionally, as stated in the first paragraph of
the Assumptions section, the AUC for TTE, TEE, and
stress echocardiography are for adult patients. Indications
for pediatric echocardiograms were not covered.
New Assumptions and Definition
In addition to adding new clinical indications and clarifying
existing indications from the original TTE/TEE AUC (1)
and stress echocardiography AUC (2), the writing group
also revised and added specific assumptions and definitions.
Several general assumptions were added. First, the assump-
tion that cost should be implicitly considered in determining
appropriate use of an echocardiogram was added. Second, a
new assumption addresses the category of uncertain indica-
tions and clarifies that such a rating should not be consid-
ered grounds for withholding reimbursement. Third, a new
assumption indicates that appropriateness ratings reflect
whether a specific test is appropriate for a given patient, not
whether it is preferred over another modality (e.g., RNI,
CT). Thus, the AUC should not be used to provide clinical
support for administrative policies regarding test prefer-
ences. Finally, an assumption clarifies that routine or sur-
veillance echocardiograms represent a “periodic” evaluation
after a certain period of time has elapsed, and are not being
ordered because of any other clinical factors. Other more
specific assumptions were also added. These include con-
sideration of prosthetic and native valves together (unless
otherwise specified) and that use of Doppler for hemody-
namics includes assessment of both right and left heart
hemodynamics. Furthermore, it is assumed that if a peri-
operative patient has symptoms or signs of cardiovasculardisease, the study should be classified under a symptomatic
indication (e.g., Indication 1), as opposed to an indication in
the perioperative category.
Similar to the RNI AUC (3), the writing group revised
the definition of “chest pain syndrome” and adopted the
term “ischemic equivalent,” which encompasses chest pain
syndromes as well as other symptoms and signs that the
clinician believes may be attributable to CAD. The writing
group also adopted the use of global risk assessment when
assessing risk in asymptomatic patients (41). This revision
was supported by the writing group, technical panel, and
external reviewers and is in harmony with the most recent
AUC for Cardiac CT (4).
Limitations
The ratings of the indications as appropriate, uncertain, or
inappropriate are reflective of the body of knowledge at the
time the rating process occurred. It is likely and expected
that as science progresses and new evidence-based guide-
lines are published, certain indications that are given 1
rating may subsequently be determined to have a different
appropriateness rating in the future. Although this neces-
sarily reflects the evolving nature of medical science, it may
also introduce apparent discrepancies between appropriate-
ness of similar indications for different modalities evaluated
at different time points. The current evidence base and
practice guidelines were used to develop the indications
whenever available, although for certain indications the
literature was limited and clinical expertise played a larger
role. This is consistent with the standard methodology and
principles of evidence-based medicine as endorsed by the
Physician Consortium for Performance Improvement (42).
dditionally, as mentioned in the previous text, certain
linical scenarios were intentionally not covered by the
ndications. When future implementation studies evaluating
his revised AUC for echocardiography are conducted, it
ay become apparent that frequent situations were not
overed. As was the case for this current revision, results and
ecommendations from implementation studies will help
hape future modifications to the AUC.
Use of AUC to Improve Care
The AUC in this report provide an estimate of whether it is
reasonable to use echocardiography for a particular clinical
scenario, specifically for 1 of the 202 indications listed in
this document. These criteria are expected to be useful for
clinicians, healthcare facilities, and third-party payers en-
gaged in the delivery of cardiovascular imaging. The AUC
is expected to be valuable across a broad range of situations,
including guiding care of individual patients, educating
caregivers, and informing policy decisions regarding cardio-
vascular imaging.
AUC represent the first component of the chain of
quality domains for cardiovascular imaging (43). After
ensuring proper test selection, the achievement of quality in
imaging includes adherence to best practices in image
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tion, as well as incorporation of findings into clinical care.
All components are important for optimal patient care,
although the development of AUC and their ranking by the
technical panel is intended to address only the first quality
domain, and assumes no barriers to other quality standards
are being met.
Although these criteria are intended to provide guid-
ance for care decisions, they cannot serve as substitutes
for sound clinical judgment and practice experience. The
writing group recognizes that patients encountered in
clinical practice may not be represented in these AUC or
may have extenuating features when compared with the
clinical scenarios presented. Additionally, uncertain in-
dications often require individual physician judgment and
an in-depth understanding of the patient to better
determine the usefulness of a test for a particular sce-
nario. As such, the ranking of an indication as uncertain
(4 to 6) should not be viewed as limiting the use of
echocardiography for such patients. It should be empha-
sized that the technical panel was instructed that the
“uncertain” designation was still designed to be consid-
ered as a “reimbursable” category.
These ratings reflect the critical medical literature as well
as expert consensus and are intended to evaluate the
appropriate use of specific patient scenarios to determine
overall patterns of care regarding echocardiography. In
situations where there is substantial variation between the
appropriate use rating and what the clinician believes is the
best recommendation for the patient, further considerations
or actions, such as a second opinion, may be appropriate.
Moreover, it is neither anticipated nor desirable that all
physicians or facilities will have 100% of their echocardio-
grams deemed appropriate. However, it is desirable, though
not realistic, that 0% be inappropriate. Related to the overall
patterns of care, if the national average of appropriate and
uncertain ratings is 80%, for example, and a physician or
facility has a 40% rate of inappropriate procedures, further
examination of the patterns of care may be warranted and
helpful. The use of AUC to guide clinical decision making
and its impact on patient outcomes and healthcare quality/
efficiency needs to be studied rigorously. AUC are also
useful as educational tools for both echocardiography pro-
viders and referring physicians. The recently announced and
soon to be implemented incorporation of AUC into echo-
cardiography laboratory accreditation requirements will en-courage their use (44). However, the greatest opportunity to
optimize the use of echocardiography is in improving
individual patient decision making. The successful applica-
tion of AUC into clinical practice represents an important
area of ongoing quality improvement.
Appendix A: Additional
Echocardiography Definitions
1. Angina
• Typical Angina (Definite): Defined as 1) substernal
chest pain or discomfort that is 2) provoked by
exertion or emotional stress and 3) relieved by rest
and/or nitroglycerin (45).
• Atypical Angina (Probable): Chest pain or discomfort
that lacks 1 of the characteristics of definite or typical
angina.
• Nonanginal Chest Pain: Chest pain or discomfort
that meets 1 or none of the typical angina
characteristics.
2. Acute Coronary Syndrome (ACS)
As defined by the ACC/AHA Guidelines for the Manage-
ment of Patients with ST-Elevation Myocardial Infarction:
patients with an ACS include those whose clinical presen-
tations cover the following range of diagnoses: unstable
angina, myocardial infarction without ST-segment eleva-
tion (NSTEMI), and myocardial infarction with ST-
segment elevation (STEMI) (46).
3. Evaluating Perioperative Risk for Noncardiac Surgery
Method for Determining Perioperative Risk
See Figure A1, “Stepwise Approach to Perioperative
Cardiac Assessment,” from the ACCF/AHA guidelines
on perioperative cardiovascular evaluation and care for
noncardiac surgery (16). Based on the algorithm, once it
is determined that the patient does not require urgent
surgery, the clinician should determine the patient’s
active cardiac conditions (see Table A1) and/or periop-
erative risk predictors (see Table A2). If any active
cardiac conditions and/or major risk predictors are pres-
ent, Figure A1 suggests consideration of coronary an-
giography and postponing or canceling noncardiac sur-
gery. Once perioperative risk predictors are assessed
based on the algorithm, then the surgical risk and
patient’s functional status should be used to establish the
need for noninvasive testing.
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Cardiac evaluation and care algorithm for noncardiac surgery based on active clinical conditions, known cardiovascular disease, or cardiac risk factors for patients 50
years of age. HR indicates heart rate; LOE, level of evidence; and MET, metabolic equivalent. Modified from (16).Table A1. Active Cardiac Conditions for Which the Patient Should Undergo Evaluation and Treatment Before Noncardiac Surgery
(Class I, Level of Evidence: B)
Condition Examples
Unstable coronary syndromes Unstable or severe angina* (CCS class III or IV)†
Recent MI‡
Decompensated HF (NYHA functional class IV; worsening
or new-onset HF)
Significant arrhythmias High-grade atrioventricular block
Mobitz II atrioventricular block
Third-degree atrioventricular heart block
Symptomatic ventricular arrhythmias
Supraventricular arrhythmias (including atrial fibrillation) with uncontrolled ventricular rate
(HR 100 bpm at rest)
Symptomatic bradycardia
Newly recognized ventricular tachycardia
Severe valvular disease Severe aortic stenosis (mean pressure gradient 40 mm Hg, aortic valve area 1.0 cm2, or
symptomatic)
Symptomatic mitral stenosis (progressive dyspnea on exertion, extertional presyncope, or HF)
*According to Campeau (47); †May include “stable” angina in patients who are unusually sedentary; ‡The American College of Cardiology National Database Library defines recent MI as 7 days but
1 month (within 30 days). Reprinted from Fleisher et al. (16).
CCS indicates Canadian Cardiovascular Society; HF, heart failure; HR, heart rate; MI, myocardial infarction; and NYHA, New York Heart Association.
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Scores
The TIMI risk score (48) is a simple tool composed of 7
(1-point) risk indicators rated on presentation. The com-
posite end points (all-cause mortality, new or recurrent MI,
or severe recurrent ischemia prompting urgent revascular-
ization within 14 days) increase as the TIMI risk score
increases. The model remained a significant predictor of
events and test sensitivity and was relatively unaffected/
uncompromised by missing information, such as knowledge
of previously documented coronary stenosis of 50%. The
model’s predictive ability remained intact with a cutoff of 65
years of age.
The TIMI risk score is determined by the sum of the
presence of 7 variables at admission; 1 point is given for each
of the following variables: age 65 years, at least 3 risk
factors for CAD, prior coronary stenosis of 50%, ST-
segment deviation on ECG presentation, at least 2 anginal
events in prior 24 hours, use of aspirin in prior 7 days, and
elevated serum cardiac biomarkers.
Low-Risk TIMI Score: TIMI score 2
High-Risk TIMI Score: TIMI score 2
5. ECG–Uninterpretable
Refers to ECGs with resting ST-segment depression
(0.10 mV), complete LBBB, pre-excitation (Wolff-
Parkinson-White Syndrome), or paced rhythm.
6. Coronary Angiography
The term coronary angiography refers to invasive cardiac
catheterization or to established noninvasive methods
of imaging the coronary arteries, such as coronary CT
angiography.
Appendix B: Additional Methods
See the Methods section of the report for a description of
panel selection, indication development, scope of indica-
tions, and rating process.
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